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Preface
“To succeed, jump as quickly at opportunities as you do at conclusions.”
Benjamin Franklin
In recent years, cancer immunotherapy has emerged as a leading way to combat 
 several different types of cancer. Although the beginnings of cancer immuno-
therapy date back to the nineteenth century and the experiments of William Coley, 
recent scientific breakthroughs have allowed medical treatments resulting in 
increased survival rates of cancer patients. Cancer immunotherapy utilizes different 
tools, including tumor antigens, cancer vaccines, adoptive cellular immunotherapy, 
natural killer cell therapy, chimeric antigen receptor T-cell (CAR-T cell) therapy, 
antibody-based therapy, and immune checkpoint inhibitors. Innovative biological 
treatments are currently being developed to target malignant tumor cells and to 
bypass the tumor evasion of the immune system. Notably, CAR-T cell therapy and 
immune checkpoint inhibitors have made waves of progress in the medical and 
scientific societies. Other therapies such as cancer vaccines remain revolutionary 
and have been accepted as forms of treatments for certain types of cancer, including 
advanced stage prostate cancer. However, challenges remain on how the research 
and medical communities will be able to efficiently harness the potential of these 
therapies with minimal side effects. The hope remains that the advancements in 
the field will allow for greater survival rates and better quality of life for patients 
inflicted with cancer.
I would like to thank all those who helped with this publication, especially Ms. 
Dolores Kuzelj. Finally, I dedicate this book to my family, my colleagues, and my 
mentors and mentees throughout my career.
Hilal Arnouk, MD, PhD
Department of Pathology,
College of Graduate Studies,
Chicago College of Osteopathic Medicine,
College of Dental Medicine-Illinois,
Chicago College of Optometry,
Midwestern University,
Downers Grove, Illinois, United States
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Chapter 1
Introductory Chapter: Are We 
There Yet? The Long and Winding 
Road to Cancer Immunotherapy
Hilal Arnouk and Sana Moqeet
1. History of cancer immunotherapy
Cancer immunotherapy has become an innovative approach that both pushes 
the medical and scientific community to better understand our own immune 
system and charts a new frontier in the fight against one of the leading killers in the 
world, cancer. The advent of this line of work dates back to the discovery of vaccine. 
Luminary scientists in the nineteenth century such as Joseph Lister, Louis Pasteur, 
Robert Koch, and most notably William Coley have allowed for a better understand-
ing of the immune responses and the establishment of vaccines, including vaccines 
directed against malignant tumors [1–4].
While the basic concept of using immunotherapy to combat cancer was 
practiced in the scientific community, specifically by Coley, scientists Thomas 
and Burney were the first to propose the theory of cancer immunosurveillance in 
1957. The premise behind their theory was that lymphocytes, an integral part of 
the immune system, have the capability to eliminate the mutated cancerous cells 
throughout the human body [5–8]. However, due to a lack of scientific proof-of-
concept and the inability to culture the lymphocytes ex vivo for extended periods of 
time, the next development did not occur until a few decades later. From the 1970s 
onward, the scientific community has discovered the utility of several different 
immune therapies to treat cancer including interferon alpha (IFN-α) [9], the T cell 
growth factor interleukin 2 (IL-2), monoclonal antibodies targeting tumor-associ-
ated antigens, and the first FDA-approved cell-based cancer vaccine developed for 
patients with advanced prostate cancer in 2010 (Figure 1).
This chapter will give a brief overview of few of these therapies that scientists 
and physicians are currently utilizing in the fight against cancer.
2. Tumor antigens
Tumor cells are distinguished from normal cells in a tissue by the presence of 
unique proteins known as tumor antigens. They can be further divided into two 
broad categories, tumor-associated antigens and tumor-specific antigens.
Tumor-associated antigens can arise from oncofetal genes that become aber-
rantly expressed in malignant cells, such as alpha-fetoprotein (AFP) in liver 
cancer and the melanoma-specific antigens of the MAGE family [10], or from 
cancer-testis antigens that are expressed normally in the germ cells and become 
activated in cancers, such as the New York esophageal squamous cell carcinoma 
1 (NY-ESO-1) antigen [11]. Tumor-associated antigens also include tissue 
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differentiation antigens, such as tyrosinase in melanoma [12], and viral antigens in 
a number of malignancies where viral oncogenesis is implicated, such as HPV E6 
and E7 oncoproteins in HPV-associated cervical cancers [13]. On the other hand, 
tumor-specific antigens are usually the products of mutated oncogenes or tumor 
suppressor genes, such as ras and p53.
3. Cancer vaccines
While it is well established that vaccines are a way to stimulate the immune 
system against infectious agents, the concept of harnessing the power of a vaccine 
to eliminate cancers remains revolutionary. Cancer vaccines work through inducing 
a specific antitumor T cell response.
Cancer vaccines are divided into prophylactic and therapeutic vaccines. For 
instance, a prophylactic vaccine against human papillomavirus (HPV) can prevent 
several cancer types caused by virus, such as cervical cancer and some cancers of 
the oropharynx [14, 15], and hepatitis B virus (HBV) vaccine provides protection 
against liver cancers initiated by the hepatitis B virus [16]. Alternatively, thera-
peutic cancer vaccines trigger an immune response against an existing tumor by 
inducing T cell response within the tumor microenvironment. Various formats have 
been developed for therapeutic cancer vaccines, including peptide fragments and 
full-length tumor antigens, vectors for genetically encoded tumor antigens, whole 
tumor cell contents, and autologous dendritic cell (DC) vaccines. Most notably, 
Sipuleucel-T (Provenge) was the first FDA-approved cell-based cancer vaccine 
developed for patients with hormone-refractory prostate cancer and has shown to 
prolong the life of affected patients by several months [17, 18].
Figure 1. 
Key events in the history of cancer immunotherapy.
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Since most tumor-associated antigens are not highly immunogenic on their own, 
an immune adjuvant is typically added to vaccine formulas. Examples of vaccine 
adjuvants include recombinant granulocyte-macrophage colony-stimulating factor 
(GM-CSF) and heat shock proteins [19–21].
4. Adoptive cellular immunotherapy
Adoptive cellular immunotherapy (ACT) is the process of transferring effec-
tor immune cells, such as T lymphocytes, to cancer patients, including modifying 
and expanding these immune cells ex vivo to target specific cancer cells [22, 23]. 
The transferred immune cells can have autologous or allogeneic origin. Two major 
approaches have been utilized for adoptive cellular immunotherapy, tumor-infil-
trating lymphocytes (TILs) and chimeric antigen receptor-modified T cell (CAR-T) 
therapy.
4.1 Tumor-infiltrating lymphocytes (TILs)
A tumor-infiltrating lymphocyte is an immune cell that has moved into a tumor 
in the attempt to destroy the cancer. In this therapy, TILs are extracted from tumor 
tissue biopsies and cultured in vitro with IL-2 to expand the tumor-reactive clones. 
Once activated, lymphocytes are infused back into the patient [24].
4.2 Chimeric antigen receptor-modified T cell (CAR-T) therapy
Chimeric antigen receptor-modified T cell (CAR-T) therapy has emerged 
as a successful method in the fight against cancer, especially B cell hematologic 
malignancies [25]. This success lies within the chimeric antigen receptors (CAR) 
composed of single-chain variable fragment (scFv) and the costimulatory signaling 
molecules that can stimulate T cells and allow for direct antigen binding and activa-
tion, bypassing the requirement for antigen presentation by antigen-presenting 
cells (APCs).
CAR-T cell therapy has been especially effective against certain types of lym-
phoma and leukemia, such as refractory B cell lymphoma and acute lymphoblastic 
leukemia (ALL) [26, 27]. CAR-T cell therapy is a multistep process. First, patients 
are evaluated to determine if CAR-T cell therapy is an appropriate treatment. 
Second, T cells are isolated from blood. The patient’s T cells are then taken into the 
laboratory to be genetically modified to express the chimeric antigen receptors 
(CARs) on their surfaces. As discussed above, these essential receptors allow for the 
modified T cells to recognize tumor antigens. Finally, the CAR-T cells are infused 
back into the patient, and a recovery period of 2–3 months is expected [28].
Overall, CAR-T cell therapy has become a leading area of continued growth and 
research in the field of cancer immunotherapy. It has had much success in both pre-
clinical and clinical applications, and the next steps involve harnessing the power 
of modified T cells to aid in eliminating solid tumors including aggressive cancers, 
such as sarcomas.
4.3 NK cell therapy
Natural killer (NK) cells are large granular lymphocytes that can destroy cells 
organically, without the requirement for priming first. One of the major hypotheses 
related to NK cells is the “missing self” hypothesis, which states that NK cells have 
the ability to destroy cells that do not display major histocompatibility complex 
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(MHC) class I molecules [29]. Given the extraordinary functions of NK cells in 
recognizing and destroying altered cells, NK cell-based therapies have become a 
wide area of research for diseases like cancer. One such targeted therapy is the use 
of NK alloreactivity, specifically in acute leukemia and other types of hematologic 
cancers. MHC class I inhibitory receptors, specifically killer immunoglobulin-like 
receptors (KIRs), have been utilized to exert NK cell alloreactivities as a way to 
combat leukemic cells [30].
5. Antibody-based treatments
Antibodies are arguably one of the most important aspects of the human 
immune system. They serve to bind to antigens and allow for flagging of cells with 
specific antigens for eradication. An antitumor monoclonal antibody is a genetically 
engineered immunoglobulin that is produced to recognize a specific tumor antigen 
on the surface of a cancer cell [31].
Monoclonal antibodies work in a multitude of ways including flagging cancer 
cells, blocking growth of cells, blocking immune inhibitors, directly attacking 
cancer cells, and bridging cancer and immune cells [32]. Monoclonal antibodies 
come in two different varieties, naked and conjugated. Naked monoclonal antibod-
ies work individually and can attach themselves to antigens on cancer cells. For 
instance, trastuzumab (Herceptin) can bind to HER2 oncogene/tumor antigen 
that is overexpressed in a subset of breast cancers, which blocks the growth and 
proliferation of the malignant cells [33]. Conjugated monoclonal antibodies work 
by carrying a radioactive or cytotoxic drug into proximity to the tumor cells, thus 
killing these malignant cells [34, 35]. As with other cancer immunotherapies, 
antibody-based treatments carry the risk of adverse side effects that include fever, 
weakness, nausea, and rashes.
6. Immune checkpoint inhibitors
Immune checkpoint inhibitors are inhibitory molecules on immune cells that 
prevent the immune system from attacking the organism’s own tissues. Two of the 
identified immune checkpoints are programmed cell death-1 (PD-1) and cytotoxic 
T lymphocyte-associated protein 4 (CTLA-4) [36].
Interaction of PD-1 and its ligand PDL-1 leads to T lymphocytes’ dysfunc-
tion and exhaustion. PDL-1 is shown to be highly expressed on cancer cells 
[37]. Consequently, the blockage of PD-1 and PDL-1 interactions using immune 
checkpoint inhibitors allows tumor-specific T lymphocytes to exert their function 
by recognizing and destroying cancer cells. Nivolumab and pembrolizumab are 
monoclonal antibodies that function as PD-1 blockers and are being currently being 
used to treat patients with advanced melanoma and non-small cell lung cancer 
[38, 39]. Similarly, CTLA-4 inhibits T cell activation. Thus, CTLA-4 blockage with 
inhibitors, such as ipilimumab, enhances the immune responses against malignant 
tumors such as melanoma [40].
It is important to note, however, that the use of immune checkpoint inhibitors 
in cancer immunotherapy is frequently followed by inflammatory and autoimmune 
side effects that include endocrine effects, rash, and hepatitis [41, 42].
In conclusion, cancer immunotherapy remains a field that has tremendously 
changed our understanding of how to best treat cancers. While advancements 
have been made, there are many more discoveries to be made as the field of tumor 
immunology is growing exponentially.
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Abstract
Recent advances in immuno-oncology have allowed for the design of more 
specific and efficient cancer vaccine approaches. There has been an improvement in 
molecular biology techniques, as well as a greater understanding of the mechanisms 
involved in the activation and regulation of T cells and the interplay between the 
components of the immune system and the escape mechanisms used by cancer 
cells and the tumour microenvironment. As a result, many interesting develop-
ments in therapeutic cancer vaccines are ongoing, with influence on survival still 
to be proven. The spectrum of tumour antigens that are recognised by T cells is still 
largely unchartered and, most importantly, dynamically evolving over time, driven 
by clonal evolution and treatment-driven selection. Vaccine approaches currently in 
development and tested in clinical studies are based on tumour antigens specifically 
identified for each tumour type, on tumour cells or dendritic cells, the latter having 
the potential to be modified to incorporate immunostimulatory genes. However, 
interplay between the immune system and the tumour and the inhibitory mecha-
nisms developed by tumour cells to subvert immune responses are crucial issues 
that will need to be targeted in order for efficient therapeutic vaccines to emerge.
Keywords: vaccine, T cells, tumour antigens, immune system
1. Introduction
Cancer constitutes one of the biggest burdens in the Western society with lung, 
breast, prostate and colorectal cancer being the most prevalent. Despite declining 
rates in the Western societies [1], there have been an estimated 9.6 million deaths 
by cancer worldwide in 2018 [2, 3], and it is expected that this number will further 
increase over time.
The molecular nature of human cancers is complex and varies among tumours 
and individuals. For that reason, the approach towards a more personalised cancer 
treatment has gained intense interest. Treatment approaches are being increasingly 
changing from histology- to molecular-based therapies, including targeting the 
interplay between cancer and the immune system.
In the last few decades, major advances have been made in recognising that an 
effective immune system—or the lack thereof—plays an important role in cancer 
development, growth and metastasis. For example, the presence of tumour-
infiltrating lymphocytes (TILs) has been identified as a positive prognostic factor in 
multiple cancer types [4]. Utilising the body’s defences and reactivating the antitu-
mour immune response, initially regarded as a simple paradigm, have created a sci-
entific and therapeutic revolution [5]. After decades of attempts, immunotherapy 
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breast, prostate and colorectal cancer being the most prevalent. Despite declining 
rates in the Western societies [1], there have been an estimated 9.6 million deaths 
by cancer worldwide in 2018 [2, 3], and it is expected that this number will further 
increase over time.
The molecular nature of human cancers is complex and varies among tumours 
and individuals. For that reason, the approach towards a more personalised cancer 
treatment has gained intense interest. Treatment approaches are being increasingly 
changing from histology- to molecular-based therapies, including targeting the 
interplay between cancer and the immune system.
In the last few decades, major advances have been made in recognising that an 
effective immune system—or the lack thereof—plays an important role in cancer 
development, growth and metastasis. For example, the presence of tumour-
infiltrating lymphocytes (TILs) has been identified as a positive prognostic factor in 
multiple cancer types [4]. Utilising the body’s defences and reactivating the antitu-
mour immune response, initially regarded as a simple paradigm, have created a sci-
entific and therapeutic revolution [5]. After decades of attempts, immunotherapy 
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has achieved a major breakthrough with the sensational successes of immunomodu-
lation with checkpoint blockade (i.e. PD-1/PD-L1 and CTLA-4 inhibitors, among 
others). In addition to that, the recent development of immune effector cell therapy 
in the form of chimeric antigen receptor T cells for haematological malignancies has 
opened exciting horizons for solid tumours as well [6, 7]. Up to now, therapeutic 
vaccination against cancer, despite few examples like Bacillus Calmette-Guérin 
(BCG) treatment for superficial bladder cancer [8], the oncolytic virus-based 
talimogene laherparepvec (T-VEC) [9] and the Sipuleucel vaccine in prostate cancer 
[10], has not achieved similar results.
Nevertheless, new vaccine development techniques as well as immunotherapy 
combination strategies shape the pipeline of current trial development and repre-
sent a promise and challenge for the future.
1.1 The T-cell response to cancer
The immune system and in particular dendritic cells (DCs) and macrophages 
are capable, to a variable extent, to recognise damage-associated molecular patterns 
(DAMPs), thus eliciting an innate immune response. The major DAMP driving 
innate host antitumour immune responses is tumour-derived DNA, which is 
detected via the stimulator of interferon gene (STING) pathway and results in type 
I IFN production [11].
The adaptive immune response begins when cancer antigens are presented to T and 
B cells by DCs. Although B-cell responses are probably playing a role in antitumour 
immunity, not much is yet known about them [12]. The following text will therefore 
mostly refer to antitumour T-cell responses. Tumour antigens are transported via 
lymphatic vessels to the lymph nodes, where they are captured by lymph node-resident 
DCs. Alternatively, tissue-resident DCs capture antigens at the tumour site and migrate 
to induce T-cell responses in the lymph node [13]. DCs present protein antigens in the 
context of major histocompatibility complex (MHC) class I and II molecules, allowing 
the stimulation of rare antigen-specific CD8+ or CD4+ T lymphocytes, respectively. 
Upon antigen encounter, CD8 T cells differentiate into cytotoxic T lymphocytes 
(CTLs) that have tumour-killing capacities, whereas CD4 T cells will provide CD8 
T-cell help [13]. CD4 T cells can also be induced to become FoxP3+ regulatory T cells 
(Tregs), which are then able to inhibit antitumoural immune responses [14].
A tumour mass is not composed solely of tumour cells, but contains immune 
cells, stromal cells and vessels, a concept known as the tumour microenvironment. 
Tumours are organised in various reciprocal, local and systemic relations with 
myeloid and lymphoid immune cell populations, both being key factors in regulat-
ing immune responses to cancer. During progression, tumours are able to modulate 
the immune response and highjack it to their advantage, in order to invade and 
grow. Macrophages can be polarised to a pro-tumoural and anti-inflammatory 
(called M2) phenotype at the tumour’s advantage. In addition, myeloid-derived 
suppressor cells (MDCSs) accumulate in the tumour microenvironment and are 
able to suppress antitumour T-cell responses [15, 16].
1.2  The three phases of tumour immunoediting: elimination, equilibrium and 
escape
The principles of cancer immunoediting have set the basis for understanding 
the dual host-protective and immuno-sculpting effects of immunity on cancer [17]. 
During cancer immunoediting, the host immune system influences tumour fate 
in three phases through activation of innate and adaptive immune mechanisms: 





The elimination phase occurs when cancer cells are eradicated by a competent 
immune system. This is evidenced by immunodeficient mice that have an increased 
propensity to develop carcinogen-induced and spontaneous cancers than wild-type 
mice [18]. In addition, tumours that come from immunodeficient mice are more 
immunogenic than those from immunocompetent mice, as they have not been edited 
by the immune response. Patients suffering from AIDS [19] or being under immu-
nosuppression are similarly more prone to develop cancer [20, 21]. The role of CD8 T 
cells has been more extensively studied; however interplay with CD4 T-cell responses 
is also required in order to have an integrated and efficient response [22, 23].
1.2.2 Equilibrium
The sporadic tumour cells that survive immune destruction will enter into the 
equilibrium phase where editing arises. Immune pressure is mostly mediated by CD4 
and CD8 T cells [24]. Upon tumour editing, more mutations will be acquired, which 
will favour entry into the escape phase of immunoediting. Importantly, the process 
of incomplete elimination promotes the generation of tumour cell variants with 
decreased immunogenicity [23]. The identification of hidden cancer cells in an equi-
librium state remains a challenge; however, advances in technology and biomarkers 
may allow for circulating tumour cells and niches to be investigated further.
1.2.3 Escape
The escape phase represents the final phase of the process, where immunologi-
cally sculpted tumours begin to grow progressively, becoming clinically apparent. 
Tumour escape can result from many different mechanisms including reduced 
immune recognition, through loss of MHC class I, co-stimulatory molecules or 
tumour antigens. In addition, the tumour induces many molecules and cells to 
induce an immunosuppressive tumour microenvironment. Cytokines such as VEGF 
and TGF-β, immunoregulatory molecules such as indoleamine 2,3-dioxygenase 
(IDO), programmed death-ligand 1 (PD-L1) and ligands for Tim3 and lymphocyte-
activation gene 3 (LAG-3), among others, are induced to supress the incoming CD4 
and CD8 T cells. In addition, many cellular components of the tumour microenvi-
ronment, such as macrophages and neutrophils, are being redirected in an anti-
inflammatory pro-tumoural state [25–27].
1.3 The principles and means of immunotherapy
Although cancer cells have the unique ability to escape from the immune 
response, the knowledge that immune cells are able to recognise tumours allows 
development of therapies that utilise the immune system [28]. Cancer immunother-
apies focus on exploiting both the innate and adaptive arms of the immune system. 
They can be classified into vaccines, monoclonal antibodies (including immune 
checkpoint inhibitors), recombinant cytokines, small molecules and adoptive T-cell 
transfer, including chimeric antigen receptor (CAR), TCR and TIL therapy [29–32].
1.3.1 Vaccines
The aim of cancer vaccination is to prime cellular immune response against 
tumour-specific antigens. Despite its limitations mainly owing to heterogeneous 
tumour antigen composition and expression and their susceptibility to various 
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has achieved a major breakthrough with the sensational successes of immunomodu-
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(IDO), programmed death-ligand 1 (PD-L1) and ligands for Tim3 and lymphocyte-
activation gene 3 (LAG-3), among others, are induced to supress the incoming CD4 
and CD8 T cells. In addition, many cellular components of the tumour microenvi-
ronment, such as macrophages and neutrophils, are being redirected in an anti-
inflammatory pro-tumoural state [25–27].
1.3 The principles and means of immunotherapy
Although cancer cells have the unique ability to escape from the immune 
response, the knowledge that immune cells are able to recognise tumours allows 
development of therapies that utilise the immune system [28]. Cancer immunother-
apies focus on exploiting both the innate and adaptive arms of the immune system. 
They can be classified into vaccines, monoclonal antibodies (including immune 
checkpoint inhibitors), recombinant cytokines, small molecules and adoptive T-cell 
transfer, including chimeric antigen receptor (CAR), TCR and TIL therapy [29–32].
1.3.1 Vaccines
The aim of cancer vaccination is to prime cellular immune response against 
tumour-specific antigens. Despite its limitations mainly owing to heterogeneous 
tumour antigen composition and expression and their susceptibility to various 
Cancer Immunotherapy and Biological Cancer Treatments
12
mechanisms of immune suppression, it is being intensively developed. Currently 
revisited with strategies aiming at combinations with other immunotherapies, 
cancer vaccines will be addressed in detail in this chapter.
1.3.2 Monoclonal antibodies
Antibodies target (a) factors that regulate signal pathways used by cancer cells 
in division and angiogenesis (such as the VEGF inhibitor bevacizumab) [33]; (b) 
tumour-associated antigens, activating antibody-dependent cellular cytotoxicity 
(such as the Her2-directed antibody trastuzumab) [34]; (c) complement-dependent 
cytotoxicity (such as the anti-20 and anti-EGFR antibodies rituximab and cetuximab); 
and (d) immune blockade with checkpoint inhibitors such as anti-CTLA4 antibodies 
(ipilimumab and tremelimumab), anti-PD1 antibodies (nivolumab and pembroli-
zumab) or anti-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) [31].
1.3.3 Recombinant cytokines
Immunostimulatory recombinant cytokines promote lymphocyte activation via 
control of transcriptional and metabolic programmes [35]. An example is recom-
binant IL-2 (aldesleukin, Proleukin®) that has been used to treat renal cancer and 
melanoma [36]. Another recombinant cytokine approved by the US Food and Drug 
Administration (FDA) for the adjuvant treatment in resected melanoma patients 
is pegylated interferon α-2β (Sylatron®), a member of the IFN cytokine family 
[37]. Concurrent administration of immunostimulatory cytokines such as IL-2 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) may also enhance 
the efficacy of antibody therapy [38]. Limitations include their antigenicity, poor 
pharmacokinetics and high toxicity [29].
1.3.4 Small molecules
The use of small molecules in cancer immunotherapy has been increasing, given 
their ability to target both intracellular and surface targets. Plerixafor is a small 
molecule that inhibits the binding interaction of stromal cell-derived factor 1  
(SDF-1) to the chemokine receptor CXCR4, used as a haematopoietic stem cell 
mobiliser [39]. This small molecule aims to prevent the development of cancer 
metastasis in cancer patients, principally in pancreatic ductal adenocarcinoma 
patients [29]. Another known small molecule called imiquimod, used for the 
treatment of basal cell carcinoma, is an agonist for toll-like receptor (TLR)-7. 
Imiquimod-mediated TLR7 activation induces production of proinflammatory 
cytokines, inhibits Tregs and induces activation of natural killer (NK) cells to 
eliminate cancer cells [29]. IDO inhibitors are being tested as well in multiple malig-
nancies, but results as monotherapy have been disappointing [40]. Combinations 
with other immunotherapeutic agents or with chemotherapy/radiation are being 
currently investigated. A much anticipated combination, however, of the small 
molecule IDO1 inhibitor with pembrolizumab failed to provide significant benefit 
in a phase 3 trial in unresectable or metastatic melanoma [41]. Finally, ongoing 
research evaluates the adenosine signalling with adenosine receptor inhibitors [42].
1.3.5 Adoptive T-cell therapy
The use of cancer patient’s own immune effector cells is a novel cancer immu-
notherapy, also called adoptive cell therapy. Starting with TILs, it has moved to the 




antibody (CARs) or a selected TCR [30]. These cells are multiplied and subse-
quently transferred back to the patient, who usually receives conditioning chemo-
therapy. TIL therapy has shown some clinical evidence of efficacy in the treatment 
of melanoma [43] and cervical cancer [44], with the LN-145 TIL therapy recently 
obtaining breakthrough therapy designation by FDA, while its potential is being 
further investigated. Generation of tumour-specific T cells through expression 
of a TCR that has shown antitumour properties is ongoing for several malignan-
cies [44]. CAR T cells, which are engineered to express part of a tumour-specific 
antibody, linked to intracellular T-cell signalling domains are gaining major interest 
[45]. Two anti-CD19 CAR T-cell therapies have so far received FDA approval in 
haematological malignancies, notably tisagenlecleucel for diffuse large B-cell lym-
phoma (DLBCL) and acute lymphoblastic leukaemia and axicabtagene ciloleucel 
for primary or transformed DLBCL, mediastinal and high-grade B-cell lymphoma 
[46]. Research on CAR T-cell therapies in solid malignancies is currently ongoing.
2. Cancer vaccines
2.1 Introduction
Cancer vaccination seeks to generate, amplify or skew (or the combination 
thereof) antitumour immunity. In order to reach such an ambitious goal, many 
approaches are in development, including the administration of tumour antigens, 
often with antigen presenting cells or other immune modulators.
Current technological advances in genomics, data science and cancer immu-
notherapy enable the fast mapping of alterations within a genome, as well as the 
rational selection of vaccine targets and on-demand production of a therapy that 
has been customised to a patient’s individual tumour. With the development of 
vaccination being promoted by emerging innovations in the digital era, vaccinating 
patients according to their individual tumour mutational profile may become the 
first truly personalised treatment for cancer.
It is important to distinguish vaccines that are designed to prevent cancer from 
the ones that are designed to treat cancer. The mode of action of the HPV vaccine 
for the prevention of cervical and other HPV-associated cancers [9] and of hepatitis 
B virus (HBV) vaccine for the prevention of HBV infection that carries a risk of 
development of hepatocellular carcinoma [47] is the prevention of infection itself. 
Their action is based on the generation of antiviral antibodies and has led to a net 
reduction in the incidence of these cancers in vaccinated individuals [48]. The 
development of therapeutic cancer vaccines has been more challenging. The nature 
of the antigen, which, in the case of therapeutic cancer vaccines, is derived from 
self-antigens against which the host has been tolerised and the presence of a hostile 
tumour microenvironment are key limiting factors.
2.2 Therapeutic vaccines
2.2.1 FDA-approved vaccines
Three therapeutic cancer vaccines have been approved by the FDA. The Bacillus 
Calmette-Guérin (BCG, TheraCys®, TICE®) vaccine, based on a live attenuated 
strain of Mycobacterium bovis, was the first approved cancer vaccine for use in non-
muscle invasive bladder carcinoma following transurethral resection. It showed a 
prolongation in disease-free survival (DFS) of 30 months in patients with blad-
der carcinoma in situ (CIS) and of 22.5 months in patients with Ta/T1 urothelial 
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[37]. Concurrent administration of immunostimulatory cytokines such as IL-2 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF) may also enhance 
the efficacy of antibody therapy [38]. Limitations include their antigenicity, poor 
pharmacokinetics and high toxicity [29].
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their ability to target both intracellular and surface targets. Plerixafor is a small 
molecule that inhibits the binding interaction of stromal cell-derived factor 1  
(SDF-1) to the chemokine receptor CXCR4, used as a haematopoietic stem cell 
mobiliser [39]. This small molecule aims to prevent the development of cancer 
metastasis in cancer patients, principally in pancreatic ductal adenocarcinoma 
patients [29]. Another known small molecule called imiquimod, used for the 
treatment of basal cell carcinoma, is an agonist for toll-like receptor (TLR)-7. 
Imiquimod-mediated TLR7 activation induces production of proinflammatory 
cytokines, inhibits Tregs and induces activation of natural killer (NK) cells to 
eliminate cancer cells [29]. IDO inhibitors are being tested as well in multiple malig-
nancies, but results as monotherapy have been disappointing [40]. Combinations 
with other immunotherapeutic agents or with chemotherapy/radiation are being 
currently investigated. A much anticipated combination, however, of the small 
molecule IDO1 inhibitor with pembrolizumab failed to provide significant benefit 
in a phase 3 trial in unresectable or metastatic melanoma [41]. Finally, ongoing 
research evaluates the adenosine signalling with adenosine receptor inhibitors [42].
1.3.5 Adoptive T-cell therapy
The use of cancer patient’s own immune effector cells is a novel cancer immu-
notherapy, also called adoptive cell therapy. Starting with TILs, it has moved to the 
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of melanoma [43] and cervical cancer [44], with the LN-145 TIL therapy recently 
obtaining breakthrough therapy designation by FDA, while its potential is being 
further investigated. Generation of tumour-specific T cells through expression 
of a TCR that has shown antitumour properties is ongoing for several malignan-
cies [44]. CAR T cells, which are engineered to express part of a tumour-specific 
antibody, linked to intracellular T-cell signalling domains are gaining major interest 
[45]. Two anti-CD19 CAR T-cell therapies have so far received FDA approval in 
haematological malignancies, notably tisagenlecleucel for diffuse large B-cell lym-
phoma (DLBCL) and acute lymphoblastic leukaemia and axicabtagene ciloleucel 
for primary or transformed DLBCL, mediastinal and high-grade B-cell lymphoma 
[46]. Research on CAR T-cell therapies in solid malignancies is currently ongoing.
2. Cancer vaccines
2.1 Introduction
Cancer vaccination seeks to generate, amplify or skew (or the combination 
thereof) antitumour immunity. In order to reach such an ambitious goal, many 
approaches are in development, including the administration of tumour antigens, 
often with antigen presenting cells or other immune modulators.
Current technological advances in genomics, data science and cancer immu-
notherapy enable the fast mapping of alterations within a genome, as well as the 
rational selection of vaccine targets and on-demand production of a therapy that 
has been customised to a patient’s individual tumour. With the development of 
vaccination being promoted by emerging innovations in the digital era, vaccinating 
patients according to their individual tumour mutational profile may become the 
first truly personalised treatment for cancer.
It is important to distinguish vaccines that are designed to prevent cancer from 
the ones that are designed to treat cancer. The mode of action of the HPV vaccine 
for the prevention of cervical and other HPV-associated cancers [9] and of hepatitis 
B virus (HBV) vaccine for the prevention of HBV infection that carries a risk of 
development of hepatocellular carcinoma [47] is the prevention of infection itself. 
Their action is based on the generation of antiviral antibodies and has led to a net 
reduction in the incidence of these cancers in vaccinated individuals [48]. The 
development of therapeutic cancer vaccines has been more challenging. The nature 
of the antigen, which, in the case of therapeutic cancer vaccines, is derived from 
self-antigens against which the host has been tolerised and the presence of a hostile 
tumour microenvironment are key limiting factors.
2.2 Therapeutic vaccines
2.2.1 FDA-approved vaccines
Three therapeutic cancer vaccines have been approved by the FDA. The Bacillus 
Calmette-Guérin (BCG, TheraCys®, TICE®) vaccine, based on a live attenuated 
strain of Mycobacterium bovis, was the first approved cancer vaccine for use in non-
muscle invasive bladder carcinoma following transurethral resection. It showed a 
prolongation in disease-free survival (DFS) of 30 months in patients with blad-
der carcinoma in situ (CIS) and of 22.5 months in patients with Ta/T1 urothelial 
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carcinoma compared to 4.9 months in bladder CIS and 10.5 months in Ta/T1 
patients treated with topical doxorubicin [49].
Sipuleucel-T (Provenge) is an autologous DC vaccine for patients with mini-
mally symptomatic or asymptomatic metastatic castrate-resistant prostate cancer 
(mCRPC). Patient’s DCs are being injected with a recombinant fusion protein, 
PA2024, which consists of a tumour antigen, the prostate acid phosphatase (PAP) 
and GM-CSF, before reinfusion. The phase 3 IMPACT study, a double-blind, pla-
cebo-controlled, phase 3 trial of 512 mCRPC patients randomised to receive either 
three infusions of Sipuleucel-T or placebo 2 weeks apart, demonstrated statistically 
significant improvement of 4.1 months in median overall survival (OS) (25.8 months 
in the Sipuleucel-T group compared to 21.7 months in the placebo group) [10]. 
However, this study elicited significant criticism in regard with the observed—albeit 
modest—OS benefit without correlation with a progression-free survival (PFS) ben-
efit or a T-cell response, the lack of association between survival benefit and T-cell 
proliferation responses, the fact that T-cell proliferative responses to the chimeric 
antigen (PA2024) did not cross-react to the physiological human PAP and hence the 
absence of alternative mechanisms to explain the survival benefit [50].
The third approved vaccine, called talimogene laherparepvec (T-VEC or Imlygic), 
is an oncolytic herpes virus 1-based vaccine for advanced melanoma. In this vaccine, 
two viral genes governing neurovirulence and blockade of antigen presentation are 
deleted, and the virus is modified to produce GM-CSF to enhance immunogenic-
ity [8]. T-VEC was approved based on data published on the phase 3 OPTiM trial. 
The vaccine virus, injected intralesionally, infects both the cancer and normal cells 
but can only replicate within cancer cells. The OPTiM trial showed more durable 
response rate (>6 months) with T-VEC than GM-CSF alone, as well as higher overall 
response rate and a longer median OS (23.3 months compared to 18.9 months with 
GM-CSF alone) in patients with stage IIIB, IIIC or IV M1a melanoma [51].
2.2.2 Mode of action of therapeutic vaccines
The mode of action of most therapeutic vaccines involves development of 
cell-mediated immunity directed against tumour antigens; such antigens ought to 
ideally not be expressed in normal cells or have restricted normal expression, be of 
high expression on cancer cells, be highly immunogenic and be necessary for cancer 
cell survival [32]. Tumour antigens can be delivered as peptides, proteins, DNA 
or viral vectors or tumour cells themselves. They are usually administered with an 
adjuvant (see Section 2.5), in order to potentiate the immune response. Tumour 
antigens can also be generated via antigen spreading, which is the exposure of novel 
antigens after an initial antitumour response [52].
2.3 Tumour antigens
2.3.1 Tumour-associated antigens (TAAs)
TAAs are self-antigens commonly expressed in a specific tumour type 
among different patients. They are derived from non-mutated proteins that are 
overexpressed in tumour cells as compared to normal cells. The first TAAs were 
discovered after the cloning of gene-encoding proteins that generated epitopes 
recognised by tumour reactive TILs [53]. The first gene discovered that was 
reported to encode a tumour antigen recognised by T cells was MAGE-1 [53]. Since 
the discovery of MAGE-1, a large number of TAAs have been described, and they 





Shared TAAs can be classified in three main groups, cancer/testis antigens, 
overexpressed antigens and differentiation antigens [54].
Cancer testis antigens (CT) are a large family of TAAs expressed in human 
tumours of different histological origins but not in normal adult tissues, with the 
exception of immune-privileged cells such as testis and placenta [55]. These anti-
gens result from the reactivation of genes that are normally silent in adult tissues 
but that are transcriptionally activated in tumours. This quasi-exclusive tumour-
restricted expression pattern (sparing normal germ cells that do not express 
HLA class I molecules) as well as their high prevalence make them ideal vaccine 
candidates [55]. They have been identified and tested in many human clinical trials 
[56]; however, there is usually very little knowledge about their specific function, 
especially with regard to tumour transformation. CT antigens include, among oth-
ers, the MAGE-A, MAGE-B, MAGE-C, NY-ESO and SSX-2 families.
Overexpressed antigens are expressed at a higher level in tumour cells than in 
normal tissues. Expression of these antigens at variable levels in normal cells 
conveys the risk of autoimmune attack upon vaccination, but a large number of 
clinical trials have used these antigens with up to now few side effects [57]. Some 
examples of this group of antigens are tumour suppressor proteins such as p53 and 
the antiapoptotic proteins hTERT and Mucin 1 (MUC-1).
Tissue-specific (cell lineage) differentiation antigens are shared between the 
tumour and the normal tissue of origin, albeit with variable specificity. They 
include carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), HER2/
neu and melanoma lineage antigens such as gp-100, Melan-A/Mart-1 and tyrosi-
nase, expressed in melanoma [58]. As for overexpressed antigens, they are endowed 
with a risk for autoimmune reactions.
The advantage of TAAs is that they are frequently expressed by the majority of 
patients and can therefore be used to treat many patients. The disadvantage of TAAs 
is the fact that some of them retain a level of expression in normal tissues, entailing 
the potential risk of autoimmune damage upon efficient vaccination. In addition, as 
TAAs derive from self-antigens, specific T cells have undergone negative selection, 
leaving only T cells with low avidity of antigen recognition, which are not able to 
generate strong immune responses.
2.3.2 Tumour-specific antigens (TSAs)
TSAs are antigens resulting from point mutations. They represent neoantigens 
mostly expressed by individual tumours. TSAs are tumour-specific, and it is usually 
viewed that their immunogenicity is not restricted by central tolerance, which is true 
when the mutated epitope is different enough from the wild-type one. Additionally, 
induced T-cell responses are not expected to result in autoimmune toxicity [59]. 
Moreover, neoantigens may be more resistant to immune selection, as they are 
critical for the oncogenic process and, therefore, essential for keeping the neoplastic 
state. In contrast, the fact that TSAs are patient-specific prevents broad vaccination 
and requires identification in a patient-specific manner. However, recent availability 
of sequencing technologies and epitope prediction algorithms allows for a rapid 
identification of potential neoantigens. Methods of in silico prediction of neo-epit-
ope candidates with a high potential for neoantigen generation potentially present in 
multiple patients. These neoantigens hold the potential for development of “off the 
shelf” T-cell therapies, aiming to complement individualised, patient- and tumour-
specific precision medicine approaches [32]. Nevertheless, it should be kept in mind 
that only a small percentage of mutations are being presented on MHC molecules at 
the tumour cell surface, making verification of the presence of a neo-epitope at the 
tumour cell surface a prerequisite [60, 61].
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2.4 Types of vaccines
2.4.1 Peptide vaccines
Peptide vaccines consist in the delivery of MHC class I- or class II-restricted 
peptide epitopes derived from tumour antigens with the intent of activating CD8+ 
and CD4+ T cells. As peptides are not immunogenic per se, they need to be injected 
with an adjuvant [62]. GM-CSF, Montanide and TLR agonists, among others, have 
shown clinical benefit in small- and larger-scale clinical trials [63–65]. Peptide 
vaccines have the limitation of being applicable only to patients that have the HLA 
allele the peptide is restricted to. In addition, most vaccines are made of MHC class 
I-restricted peptides, therefore not eliciting CD4 T-cell help [66, 67]. In order to 
overcome this issue, the addition of non-tumour-specific peptides has been used, 
but limited data is available on the improvement provided by such heterologous 
helper peptides [68]. Overall, the numerous clinical trials performed in different 
tumour types have not provided satisfactory results yet [69].
Using multiple peptides derived from different TAAs targeting several anti-
gens at once could overcome such tumour escape mechanisms. This multipeptide 
approach has demonstrated in in vitro and in vivo studies that multiple peptides 
do not compete for MHC presentation, inducing a multi-specific T-cell response 
[70–72]. The use of synthetic peptides with improved DC-targeting mechanisms, 
such as integrating pattern recognition receptors or TLRs [73], the conjugation of 
synthetic peptides to a DC-targeting antibody [74] or the encapsulation of long 
peptides in structures such as nanoparticles, liposomes or nano-hydrogel systems to 
enhance T-cell priming by DCs [75, 76] are some of the strategies under investiga-
tion towards a more efficient processing and presentation pathway that would lead 
to greater T-cell activation.
In two trials (a phase 1 and a randomised phase 2) combining single-dose 
pre-vaccine cyclophosphamide with IMA901, a renal cell carcinoma (RCC) peptide 
vaccine containing 10 antigens (9 HLA class I-binding and 1 HLA class II-binding) 
adjuvanted with GM-CSF in HLA-A02+ subjects showed that there was an improve-
ment in survival with amplification of antigenic response and a reduction in 
suppressive circulatory T cells and MDSCs, with a disease control rate (DCR) at 
6 months of 31% (95% CI: 3–35%) [77]. Mouse models also support combinations 
of multipeptide vaccines and chemotherapy. However, the addition of IMA901 to 
first-line sunitinib (an anti-angiogenic tyrosine kinase inhibitor) failed to show 
improvement in metastatic renal cancer, owing to low-level immune responses [78], 
despite the fact that sunitinib has been shown to decrease the number of Tregs in 
mice and patients with RCC [79, 80], as well as MDSCs in patients with RCC [81].
Owing to their tumour specificity, much effort has been made in order to exploit 
neoantigens for vaccine development. Such neoantigen-directed vaccines have 
been developed for melanoma, using either synthetic RNAs containing up to 10 
predicted neoantigens or long peptides targeting up to 20 neoantigens [82, 83]. In 
these trials, neo-epitopes were chosen to bind HLA class I [82] or HLA class I and 
II molecules [83] and showed activation of CD4+ and CD8+ T cells in response to 
vaccination.
Peptide vaccines can also be helpful in the prevention of the progression of a 
premalignant lesion to cancer. The MUC-1 peptide vaccine has been tested as a 
prevention of progression of colon adenoma to colorectal cancer [84]. MUC-1 was 
highly immunogenic in about half of the patients evaluated. Moreover, response to 
the vaccine correlated with prevaccination levels of circulating MDSCs, as nonre-
sponders had a significantly higher percentage of MDSCs (p < 0.05); interestingly, 




NeuVax is a peptide vaccine that has been developed for early-stage node-
positive low or intermediate HER2-expressing breast cancer after standard of 
care treatment [85]. The vaccine is composed of a peptide isolated from HER2/
neu proto-oncogene combined with GM-CSF. Final results of a phase 1/2 clinical 
trial showed a non-significant improvement in 5-year DFS of 89.7% in the vaccine 
group versus 80.2% in the control group (p = 0.08); the improvement in DFS was 
even greater in the sub-group of optimally dosed patients (94.6%; p = 0.05 versus 
the control group) [86]. The vaccine is now being tested in an ongoing phase 3 trial 
(NCT01479244).
CDX-110 is a peptide vaccine also known as the rindopepimut vaccine. It is a 
14-mer peptide covering the EGFRvIII mutation (the commonest form of EGFR 
mutation in human glioblastoma multiforme (GBM), detected in 23–33% of 
tumours) [87], and it is linked to the adjuvant keyhole limpet hemocyanin (KLH) 
to stimulate a specific immune response against EGFRvIII expressing tumour cells. 
This vaccine has been evaluated in three phase 2 clinical trials (ACTIVATE, ACT 
II and ACT III trials) for newly diagnosed GBM and one phase 2 (ReACT trial) for 
recurrent GBM. The ACTIVATE trial demonstrated that patients with EGFRvIII-
specific humoral responses had an improved median OS as compared to patients 
not displaying immune responses (47.7 months vs. 22.8 months OS) [88]. The ACT 
II and ACT III clinical trials demonstrated longer PFS and OS than with historically 
matched controls [88, 89]. Deceivingly, the phase 3 trial ACT IV for newly diag-
nosed GBM was terminated for futility at the second preplanned interim analysis 
(HR: 0.99 for rindopepimut versus control, 95% CI: 0.74–1.31) [90]. A lack of 
benefit was also observed in the intention-to-treat population. The study confirmed 
earlier-phase trial findings of rindopepimut-induced EGFRvIII-specific antibody 
responses in the majority of patients; however, the fact that loss of EGFRvIII was 
observed in patients receiving or not the vaccine suggests that this target is unstable 
and therefore not a suitable antigen for immunotherapy. The phase 2 ReACT trial, 
evaluating the combination of bevacizumab and rindopepimut for recurrent GBM, 
showed that the vaccine induced robust anti-EGFRvIII antibodies in the majority of 
patients. The primary endpoint of PFS at 6 months was improved for the rindopep-
imut arm, albeit non-significantly (28% vs. 16%, p = 0.12), with a similar outcome 
for OS and duration of response. Rapid anti-EGFRvIII antibody generation was 
shown to be associated with prolonged OS in the rindopepimut arm [91]. A major 
criticism for this study, which could explain the non-significant results, is that the 
EGFRvIII status was principally decided on diagnostic tumour specimens, despite 
the known fact that EGFRvIII expression is lost in half of tumours upon recurrence.
2.4.2 DC vaccines
In order to improve peptide presentation in vivo, cancer vaccines using DC have 
been developed. DC-based vaccines are safe and immunogenic, and they have the 
ability to promote clinically significant tumour regression in some patients [92–94]. 
Clinical trials performed with DC-based vaccines usually involve an individualised 
patient vaccination approach with single clinical trial arms, which makes it difficult 
to evoke firm conclusions about their efficacy. Several cells such as monocytes and 
CD34+ progenitor cells, antigens including complex tumour lysates and synthetic 
MHC class I-restricted peptides have all been used in different trials [95]. Some 
promising and important clinical trials involving DC vaccines have been published. 
Sipuleucel-T (Provenge) is one of the three FDA-approved vaccines (see Section 
2.2.1). In addition to the IMPACT trial that led to FDA approval, 42 men with localised 
prostate cancer received Sipuleucel-T in a phase 2 study prior to radical prostatectomy 
[96]. Increased incidence of T cells was observed in the post-operative prostate gland 
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histology compared to preoperative biopsies. Currently, clinical trials are investigat-
ing combination of Sipuleucel-T with other approved drugs, such as abiraterone 
acetate, enzalutamide, radium-223, ipilimumab and atezolizumab (NCT01487863, 
NCT01981122, NCT02463799, NCT01832870, NCT01804465, and NCT3024216).
A clinical trial that used DCs loaded with a MUC-1-derived peptide and heter-
ologous pan DR epitope (PADRE) peptides (universal CD4 T-cell helper peptides) 
delivered subcutaneously in patients with RCC has shown encouraging objective 
clinical responses and immunologic responses [97]. A phase 1/2 clinical trial used 
autologous WT-1 (Wilms’ tumour 1, a shared TAA) mRNA-loaded DCs in patients 
with acute myeloid leukaemia (AML) in remission after standard of care, with 
the aim of eradicating or controlling residual disease. This study showed clini-
cal responses correlating with increased WT-1-specific CD8+ T-cell frequencies, 
as well as elevated levels of post-vaccine-activated NK cells [98]. Another study 
used patient-derived AML cells fused with autologous DCs vaccination in post-
chemotherapy remission AML patients, achieving a marked rise in circulating T 
cells recognising whole AML cells and leukaemia-specific antigens that persisted for 
more than 6 months, which was associated with prolonged survival [99].
DCVax is a DC vaccine that has been developed for GBM. Two phase 1/2 studies 
tested the vaccine, which collectively recruited 39 patients, 20 of whom had newly 
diagnosed GBM and the remaining had recurrent high-grade glioma [100, 101]. For 
the newly diagnosed patients, the median OS with the addition of DC vaccine to 
the standard of care chemoradiation was 36 months. Long-term survival was also 
reported for some patients; 33% of patients reached or exceeded a 4-year survival, 
27% reached an OS of 6 years, and two patients achieved a 10-year survival. The first 
report of the DCVax 2:1 randomised phase 3 trial in newly diagnosed GBM unfortu-
nately does not allow interpretation as it is endowed with methodological flaws [102].
Some findings have suggested that the current DC vaccines can be optimised in 
order to get improved clinical outcomes. The discovery that the overexpression of 
CD40L in human DCs produces an increased stimulation of the T-cell response to 
tumour antigens such as gp100 and Melan-A is promising [103]. Additionally, DC 
function can be enhanced by stimulating antigen-specific Th1 and CTL responses 
through modulation of other co-stimulatory or co-inhibitory molecules, such 
as PD-1, CTLA4, CD28, OX40, etc. [104, 105]. On the contrary, suppressing the 
ubiquitin-editing enzyme A20 or the scavenger receptor SRA/CD204 in human DC 
helps in the development of IFN-α-producing Th1 cells and antigen-specific CD8+ 
T cells [106, 107]. These developments suggest that there is promising data for the 
future in DC-based cancer vaccines.
2.4.3 Tumour cell vaccines
Tumours concentrate a high number of genetic modifications in somatic cells 
and therefore carry a large number of potential antigens. For that reason, vaccina-
tion with whole tumour cells has been an interesting strategy, with the limitation 
that they need to be patient-tailored. Autologous tumour cell vaccines have been 
evaluated in several cancer types such as lung cancer [108], melanoma [109, 110], 
RCC [111], prostate cancer [112] and colorectal cancer [113, 114]. In order to 
prepare the vaccine, a large amount of tumour tissue needs to be collected, which 
impedes its application in some tumour types or some individuals.
MVX-ONCO-1 is an autologous tumour cell vaccine containing irradiated 
tumour cells from a patient and a capsule implanted with a genetically modified 
allogeneic cell line that continuously releases the adjuvant GM-CSF [115]. Results of 
the first-in-human phase 1 trial testing of this vaccine reported an excellent safety 




Over 50% of patients (8/15) experienced either partial response (PR) or stable 
disease (SD) including disappearance of lung metastases, with interesting activity 
in head and neck squamous cell carcinoma (HNSCC) and chordoma [117]. A phase 
2 trial is ongoing in HNSCC (NCT02999646).
Canvaxin was the first allogeneic whole-cell vaccine to be developed and 
consisted of three melanoma cell lines in combination with BCG as adjuvant [118]. 
It showed promising results in a phase 2 clinical trial [119, 120], but failed in the 
randomised phase 3 trial [121]. Although the reasons for the lack of efficiency 
remain to be determined, it is possible that the induced immune response was not 
able to control the disease. To potentiate induction of immune response, tumour 
antigens utilised in vaccines should be linked with potent immunological adjuvants 
[122]. Such examples are tumour vaccines that have been modified genetically to 
express co-stimulatory molecules and/or cytokines. Such an example is the GVAX 
vaccine, an allogeneic whole-cell vaccine modified with the GM-CSF gene, which 
has been evaluated for recurrent prostate cancer [123, 124], breast cancer [125] and 
pancreatic cancer [126, 127], but impact on patient survival remains to be proven.
In order to improve the immunogenicity of allogeneic tumour cells, cell lines 
have been engineered to secrete antisense oligonucleotides to inhibit expression 
of immunosuppressive cytokines, such as TGF-β. The tumour vaccine Lucanix 
(Belagenpumatucel-L) has been designed using this strategy to target metastatic 
NSCLC and has shown significant improvement in OS in two phase 2 clinical trials 
[128, 129]. However, the phase 3 clinical trial in stage III/IV patients did not dem-
onstrate prolongation of OS in the whole cohort of patients, a survival benefit being 
however observed in several subgroups of patients [130].
BiovaxID is a patient-specific therapeutic cancer vaccine composed of the 
patient clonal immunoglobulin molecule idiotype vaccine conjugated to the adju-
vant KLH. In a phase 2 clinical trial, the administration of BiovaxID together with 
GM-CSF in patients diagnosed with follicular lymphoma in complete remission 
with minimal residual disease demonstrated induction of tumour-specific cel-
lular and humoral immune responses, which translated into clinical benefit, with 
a median DFS of 8 years and an OS rate of 95% at 9 years [131]. A randomised, 
controlled phase 3 trial in patients achieving remission after chemotherapy showed 
a median DFS after randomisation of 44.2 months for the vaccine arm versus 
30.6 months for control arm [132]. However, other phase 3 trials failed to demon-
strate increase in survival for patients receiving the vaccine [133, 134].
The HyperAcute vaccines are made of tumour cell lines that have been genetically 
engineered to express the α(1,3)-galactosyltransferase enzyme in order to induce an 
hyperacute reaction with complement- and antibody-dependant cytotoxicity [135]. 
They have been tested in several malignancies including melanoma, pancreatic 
and prostate cancer [136–138] and showed encouraging results improving OS. This 
vaccine was further evaluated in two phase 3 clinical trials. The IMPRESS study 
evaluated the vaccine with or without gemcitabine/chemoradiation in resected pan-
creatic cancer patients but failed to achieve its primary endpoint, with no observed 
statistically significant difference between the treatment and control groups. The 
PILLAR trial for borderline resectable (stage II) and advanced unresectable (stage 
III) pancreatic adenocarcinoma patients, combining the vaccine with FOLFIRINOX 
or gemcitabine/nab-paclitaxel and chemoradiation, is currently ongoing.
2.4.4 Heat shock protein vaccines
Heat shock proteins (HSPs) are a group of intracellular protein chaperones. 
Their function is to protect cells from protein misfolding, dysfunction and cell 
apoptosis, and they have been implicated in the activation of innate and adaptive 
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2.4.4 Heat shock protein vaccines
Heat shock proteins (HSPs) are a group of intracellular protein chaperones. 
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apoptosis, and they have been implicated in the activation of innate and adaptive 
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immunity [139]. Therapeutic HSPs vaccines utilise HSPs as a source of tumour-
associated antigens and involve isolation and purification of HSPs from a patient’s 
tumour with subsequent reinfusion of the complex. The advantages of this type of 
vaccines are, similarly to tumour vaccines, that they do not require a pre-identifica-
tion of tumour antigens and provide several targets at the same time.
GBM are natural inducers of HSP expression, making them an interesting target 
for HSP vaccines [139]. A phase 2 trial testing the HSPPC-96 vaccine in recurrent 
GMB patients showed a 90.2% 6-month OS and a 29.3% 12-month OS, with an 
interesting observation of an adverse effect of lymphopenia on the vaccination 
outcome [140]. Adjuvant vaccination following standard treatment by surgery and 
chemoradiation in patients with newly diagnosed GBM showed a median OS of 
23.8 months [141]. Interestingly, this phase 2 trial showed better outcome (median 
OS: 44.7 months) in patients with low PD-L1-expressing myeloid cells than patients 
with high PD-L1 myeloid expression (median OS: 18 months) [141]. Nevertheless, 
a phase II randomised study (Alliance A071101) evaluating the combination of 
HSPPC-96 vaccine with bevacizumab versus bevacizumab alone in patients with 
recurrent GBM failed to demonstrate a survival benefit [142]. HSP-based vaccine 
has also been tested in various malignancies [143].
2.4.5 Viral vectors
Delivery of tumour antigens can be achieved using viral vectors. The advan-
tage of virus-based vaccines is that human immune system has evolved to react 
efficiently against them with innate and adaptive responses, inducing long-lasting 
immunity. The most common viruses from which viral vaccines vectors have been 
developed are poxviruses, adenoviruses and alphaviruses [144]. A potentially 
restraining factor using viral vectors is the fact that the induced antiviral immune 
response will neutralise the vector, limiting efficacy of repeated vaccination with 
the same vector. In order to overcome this, heterologous prime-boost vaccination 
is used, where initial delivery of a tumour antigen with one virus vector is followed 
by a boost with the same tumour antigen delivered with another virus vector [145]. 
Using viral vector also offers the possibility to insert genes coding for adjuvants 
such as GM-CSF and IL-2.
As an example, the TRICOM vaccine platform exploits heterologous prime-
boost vaccination where priming is achieved using a vaccinia vector encoding a cho-
sen TAA and boosting using a fowlpox-derived vector encoding the same TAA. In 
addition, it incorporates three co-stimulatory molecules for immune activation 
and has been used in several trials in various malignancies. In men with CRPC, the 
PROSTVAC vaccine phase 3 trial, using PSA as antigen, failed to positively influ-
ence OS [146], although phase 2 trials were encouraging [147, 148]. An analysis of 
immune response to the PROSTVAC vaccine on pooled data from several clinical 
trials conducted similarly reported that 68% of the tested patients exhibited evi-
dence of cross-priming with immune responses mounted against TAAs not found 
in the vaccine, for example, MUC-1, PSMA, PAP and PSCA, a phenomenon known 
as antigen spreading [149]. Other applications of the TRICOM vaccine in breast 
and ovarian cancer [150], solid carcinomas [151, 152], colorectal carcinoma [153] or 
advanced cancers [154] have been tested in phase 1 trials using various antigens and 
virus vectors, and further studies are planned.
Another example is BN-CV301, a poxvirus-based vaccine that codes for the 
MUC-1 and CEA TAAs. The phase 1 clinical trial showed no dose-limiting toxicity; 
the vaccine produced one PR in one patient and prolonged SD in multiple patients, 




Similarly, a first-in-human trial of the LV305 vaccine, a vaccine using DCs trans-
duced with a lentivirus expressing the NY-ESO-1 antigen, demonstrated a favour-
able safety profile with grade 1/2 event such as fatigue (49%), injection (46%) and 
myalgia (21%); induction of anti-NY-ESO-1-specific CD4+ and CD8+ responses were 
observed, with a DCR of 56.4% in all patients and 62% in sarcoma patients [159].
2.4.6 Oncolytic virus vaccines
Oncolytic viruses are a particular category of viruses that have the characteristic 
of infecting both healthy and tumour cells, but of selectively replicating only in the 
latter. They therefore kill tumour cells, additionally inducing activation of innate 
and adaptive immune responses through immunogenic tumour cell death [156]. As 
for viral vectors, they also offer the possibility to express cytotoxic or immunomod-
ulatory molecules. The herpes virus vaccine called T-VEC, engineered to selectively 
replicate in tumour cells and to secrete GM-CSF, has been approved by the FDA for 
intratumoural administration for stage IIIB/C-IV melanoma based on the phase 3 
OPTiM trial [51, 157], as mentioned above (see Section 2.2.1). A recently reported 
series of off-trial uses of T-VEC in early advanced melanoma (stages IIIB/C-IVM1a) 
showed a CR rate of 61.5% and a PR rate of 26.9, with a DCR of 92.3% [158].
T-VEC is also being tested in other malignancies. In HNSCC, T-VEC was used in 
combination with standard chemoradiation for untreated unresectable stage III/IV 
disease in a phase 1/2 trial. At a median follow-up of 29 months, PFS was 76%, very 
importantly demonstrating the safety and feasibility of this combination approach 
[159]. The initial design of the phase 3 trial was subsequently modified in view of the 
introduction of pembrolizumab in the standard of care management of HNSCC and 
was redesigned as a phase 1b trial randomising patients to pembrolizumab with or 
without T-VEC delivered to involved cervical nodes (MASTERKEY-232, NCT2626000). 
This trial showed a manageable safety profile, with however 24/36 (66.7%) patients 
experiencing serious adverse events, including one vaccine-related death. The overall 
response rate was 16.7%, the majority of which was in patients with PD-L1-positive 
tumours, and the DCR was 38.9% (again mostly in PD-L1-positive tumours) [160].
2.5 Vaccine adjuvants
Vaccination “per se” can activate antigen-specific T cells. However, when the 
antigen is in the form of peptides, proteins or even tumour cells, they are usually 
not strong enough to induce an immune response that leads to tumour eradication. 
The reason for this is that these antigens come without pathogen-associated molec-
ular pattern (PAMPs) that can be recognised by innate immune cells. Most cancer 
vaccines are therefore combined with adjuvants, which, in addition to eliciting an 
innate immune response, have the role of protecting the antigen from degradation, 
ensuring prolonged release and promoting antigen uptake by DCs. The efficiency 
and choice of the adjuvant heavily influences the vaccine efficacy.
Adjuvants that act as delivery systems are classified into virosomes, liposomes, 
the saponin QS-21, mineral salts and the water-in-oil emulsion Montanide (an 
incomplete Freund’s adjuvant analogue). Montanide is used in many trials of 
peptide vaccines and is generally well tolerated [61]. Aluminium is mostly used 
for antiviral vaccines such as the HPV vaccine as it promotes humoral rather than 
cellular responses [61]. Immunostimulatory complexes (ISCOMs) are ring-like 
structures containing lipids and saponin and can incorporate the antigen for opti-
mal presentation for DCs. GM-CSF, which is employed to recruit and activate DCs 
at the injection site, is also being used in a large number of trials [61].
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Innate immune stimulatory adjuvants are dominated by TLR ligands, but STING 
ligands, C-type lectin receptor (CLR) ligands and RIG-like receptor (RLR) ligands 
are also being tested [161]. TLR ligands induce a strong activation of DCs, and cur-
rently tested molecules include agonists to TLR2, TRL3 (e.g. the dsRNA analogue 
poly-ICLC), TLR7/8 (e.g. imiquimod) and TLR9 (e.g. the bacterial dinucleotide 
DNA CpGs). Many trials using CpGs have demonstrated its potential to improve 
T-cell responses, but it is now difficult to have access to it. Imiquimod is approved 
for the treatment of basal cell carcinoma and is used in combination with vaccines 
in several trials [61]. The TLR4 agonist glucopyranosyl lipid A (GLA) is currently 
used as adjuvants in peptide vaccines, such as with the NY-ESO-1 antigen [166]. 
Use of poly-ICLC is increasing, mostly for GBM vaccine trials, at it has proposed to 
favour T-cell homing to the brain [162].
Although many of the above-mentioned adjuvants are promising, the fear that 
using them alone would not induce strong enough immune response has led to 
development of combination strategies. Montanide is commonly used to protect 
the antigen in combination with a TLR ligand to promote inflammation. However, 
combining several immunostimulatory adjuvants such as two or more TLR ligands 
is being tested. Many more combination can be envisaged as long as safety is 
preserved.
2.6 Vaccine combinations
Vaccines, when efficiently designed, have the ability to induce strong T-cell 
responses. However, this does not imply that these T cells will be allowed to func-
tion at the tumour site, for several reasons. These include, among others, the immu-
nosuppressive tumour microenvironment and the induction of immune checkpoint 
molecules on T cells. In an attempt to target these mechanisms, many combinations 
of vaccines with other immunotherapeutic strategies are currently in development. 
Checkpoint inhibitors, agonist antibodies and immunostimulatory cytokines can 
increase tumour cell immune destruction. Moreover, combining with radiotherapy, 
hormonotherapy and chemotherapy may also be synergistic.
2.6.1 Vaccines + checkpoint inhibitors
2.6.1.1 Vaccine + anti-CTLA-4 antibodies
CTLA-4 is expressed on T cells after activation as part of the normal regula-
tion process of immune responses. However, in the case of antitumour responses, 
function of T cells need to be sustained, which is prevented by CTLA-4 expression 
[163]. To prevent that, two anti-CTLA-4 monoclonal antibodies, ipilimumab and 
tremelimumab, are currently in various stages of clinical development in combina-
tion with vaccines.
As examples, the PROSTVAC vaccine was tested with ipilimumab in mCRPC 
in a phase 1 escalation clinical trial. As a result, 14 of the 24 chemotherapy-naïve 
patients had reduction in PSA. Median OS was 31.3 months, which was longer 
than PROSTVAC alone [164]. This vaccine is currently being tested in com-
bination with other checkpoint inhibitors (NCT2506114, NCT02933255, and 
NCT03532217).
GVAX was studied in combination with ipilimumab in 28 mCRPC patients in a 
phase 1 trial. Around 39% grade 3/4 irAEs were seen (most common: hypophysitis, 
alveolitis and hepatitis). About 25% had >50% decline in PSA, while 53.5% had 




pancreatic adenocarcinoma patients, versus ipilimumab alone [166]. The combina-
tion arm showed that three patients had extended SD and seven patients had a 
reduction in their tumour marker.
2.6.1.2 Vaccines + PD-1/PD-L1 inhibitors
PD-1 is a protein expressed on T cells, some B cells and NK cells, and bind-
ing of its ligands PD-L1 and PD-L2 results in cell inhibition [163]. PD1 ligands 
can be expressed not only by tumour cells but also by other cells of the tumour 
microenvironment, and PD-L1 has been shown to be induced as a result of T-cell 
activity [167]. The blocking of this interaction is being tested with the aim to allow 
prolonged T-cell activity to take place, and several anti-PD1 (pembrolizumab and 
nivolumab, among others) and anti-PD-L1 (atezolizumab, avelumab and dur-
valumab) antibodies have been developed.
Among others, combination of nivolumab with a multipeptide vaccine has 
been evaluated for the adjuvant treatment of high-risk melanoma. Results were 
promising, showing a median PFS of 47.1 months compared to historical median of 
5–7.2 months with other approaches [168].
Pembrolizumab has been combined with a DNA vaccine encoding PAP in 
mCRPC patients. PSA responses were more important in the cohort receiving 
concurrent than sequential treatment. PSA declines were associated with the 
development of PAP-specific Th1-biased T-cell immunity and CD8+ T-cell infiltra-
tion in metastatic tumour biopsy specimens. No confirmed CR or PR was observed; 
however, 4/5 patients treated concurrently had measurable decreases in tumour 
volume at 12 weeks [169].
A multitude of studies are currently testing vaccines combinations with check-
point inhibitors for different malignancies.
2.6.2 Vaccines + tyrosine kinase inhibitors
Tyrosine kinase inhibitors (TKIs) have been used for the treatment of several 
solid tumours and haematological malignancies. There is preclinical and clinical 
data proposing that TKIs have an “off-target” effect on immune cells that restraint 
and/or intensify the antitumour response [170].
A phase 3 trial evaluating the combination of sunitinib with a modified vaccinia 
Ankara-based vaccine encoding the tumour-associated antigen 5T4 (MVA-5T4) was 
not able to demonstrate benefit in OS, although patients with good-risk tumours 
responded better to the combination [171].
Based on the positive results of a phase 3 trial evaluating the epidermal growth 
factor (EGF) vaccine CIMAvax-EGF as switch maintenance therapy versus placebo 
for previously chemo-treated advanced NSCLC patients [172], a phase 1b study 
evaluating the CIMAvax-EGF vaccine in combination with EGFR TKI in EGFR-
mutated NSCLC tumours (EPICAL trial) is currently ongoing (NCT03623750).
2.6.3 Vaccines + endocrine treatment
Endocrine treatment is important in hormonally driven tumours like prostate 
and breast cancer. Patients treated with letrozole, an aromatase inhibitor used for 
the adjuvant treatment of hormone-responsive breast cancer, were found to have 
less Tregs in the tumour microenvironment [172]. In addition, androgen depriva-
tion therapy in prostate cancer patients generates an immunostimulatory microen-
vironment increasing the number of effector T cells [173, 174].
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A post hoc analysis of a phase 3 randomised trial of the Sialyl Tn-KLH vaccine in 
women with metastatic breast cancer indicated an improved clinical outcome with 
the addition of concomitant endocrine therapy, with prolonged time to progression 
and OS [175]. The order of sequential treatment seemed to be important; a combi-
nation crossover study of nilutamide with a PSA-encoding poxvirus-based vaccine 
in non-metastatic CRPC suggested improved OS when the vaccine was adminis-
tered before the hormonotherapy [176].
These combinations are attractive therapy options for hormonosensitive cancers 
because vaccines are minimally toxic and can easily be incorporated into standard 
of care regimens.
2.6.4 Vaccines + chemotherapy
Chemotherapy agents are known to induce reduction in both CD4+ and CD8+ 
T cells, however still allowing for immune responses to occur [177]. Several 
chemotherapeutic agents such as gemcitabine, taxanes, topoisomerase inhibitors, 
platinum compounds and 5-FU have been shown to produce immunomodulatory 
effects [177, 178].
The OPT-822 vaccine in combination with cyclophosphamide was tested in a 
phase 2/3 study in metastatic breast cancer versus cyclophosphamide plus placebo. 
The vaccination arm failed to show a PFS or interim OS benefit in the overall study 
population; however, they were significantly improved in the 50% of patients that 
developed an immune response to the vaccination [179].
IMA950 is a multipeptide GBM-specific vaccine composed of tumour-associated 
MHC class I- and II-restricted peptides [179]. The vaccine has been combined with 
standard chemoradiotherapy and adjuvant temozolomide in patients with newly 
diagnosed GBM in two reported trials. A phase 1 study of IMA950 adjuvanted 
with GM-CSF showed that the primary immunogenicity endpoint of observing 
multi-antigen responses in at least 30% of patients was reached. PFS was 74% at 
6 months and 31% at 9 months [180]. The second clinical trial was a phase 1/2 trial 
of the IMA950 vaccine adjuvanted with poly-ICLC in high-grade gliomas; CD8 
T-cell responses to a single or multiple peptides were observed in 63.2% and 36.8% 
of patients, respectively, while median OS was 19 months, comparing favourably to 
classical chemoradiation results [181]. A phase 1/2 trial evaluating the combination 
of the IMA950 vaccine with pembrolizumab in recurrent GBM is currently ongoing 
(NCT03665545).
2.6.5 Vaccines + radiotherapy
The concept of synergy between vaccines and radiotherapy attracts growing inter-
est in cancer therapy. One of the hypotheses to explain this is that radiation can not 
only elicit a tumour-specific immune response locally but also at distant sites, there-
fore acting as an in situ vaccine, eliciting both local and systemic responses [182]. 
Many trials have tested and are currently testing vaccines and radiotherapy, and hope 
is that they will provide important information on how to optimise cancer vaccines.
3. Conclusions
Vaccine immunotherapy currently shows a prolific activity in early phase trials 
and an expanding pipeline, with however few successes in late phase trials, despite 
encouraging or promising early results, resulting in a limited number of approved 




vaccine studies reported in the early or mid-2000s, without further translation or 
progression to later trial phases.
As our understanding of the potential of immunotherapy expands so does the 
list of research questions that will need to be answered before this approach can 
be translated for effective clinical use. Can the thus far limited success, reflected 
by the very few approved drugs, be attributed to suboptimal or inadequate trial 
design? What is the optimal endpoint for vaccine trials? How long would we need to 
treat patients with immune modulatory therapies? What is the best combination of 
approaches? What is the optimal sequence strategy?
It is evident that, in order to proceed in the next stage of therapeutic vaccine 
development, paradigm changes ought to probably be made towards more optimal 
utilisation of resources and therapeutic potential. We need a clearly defined clinical 
readout for therapeutic response, and we need a blueprint for successful translation. 
We might need to consider that the concept of using vaccines in stage IV disease is 
not the correct way forward, but rather bringing vaccines in earlier disease stages 
and developing adjuvant or maintenance strategies. In this context, OS might not be 
the correct endpoint to use, but disease-free or relapse-free survival might be more 
appropriate. Our understanding of the evolution of immune escape is still incom-
plete, and additional work must be done to identify those patients who will benefit 
most from immunotherapy and to develop novel strategies.
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Chapter 3




While the interest in cancer vaccines is renewed by some results in vaccine-
based clinical trials, the premise still suffers from the incomplete concept of a 
successful vaccine. Future progress may come from matching preclinical data with 
clinical expectations while taking a step back to understand the systems perspec-
tive. A field that benefits most from this bird’s eye view is tumor immunology. For 
instance, the accumulation over the last three decades of clear associations of T and 
B cell cross-reactivity between a set of host targets of autoimmunity and microbial 
antigens strongly supports a pathogenic role for molecular mimicry. Mimicry on its 
turn invites the concept of networks of molecular interactions. The intentional and 
rational approach to exploit mimicry in cancer vaccine development, while littered 
with failure, has provided also some insight into success. Here, we visit successes 
and underlying rationale to lend to future development of mimetic vaccines in 
immune-oncology.
Keywords: vaccine, anti-idiotype, peptide, tumor associated carbohydrate antigens, 
carbohydrate mimetic peptide
1. Introduction
Targeting malignancies through manipulating the immune system has seen 
success in a variety approaches ranging from whole cell vaccination, to autologous 
dendritic cell based vaccines and therapeutic immune-modulation [1–5]. But a 
number of opportunities and challenges remain. While tumor antigen identification 
from sequencing the cancer genome continues to be a high priority we now know 
that tumor antigens arise from multiple mechanisms that include somatic muta-
tions, translocations, and amplifications and post-translational modifications. The 
role of post-translational modification with tumor associated carbohydrate antigens 
(TACA) in the generation of novel cancer antigens is in particular an opportunity to 
be explored [6–9].
Characterizing and overcoming the immunosuppressive environment of the 
tumors has led to a focus on downstream checkpoints that regulate activated T cells, 
or on vaccination and T cell adoptive transfer to expand the T cell pool [10–12]. 
However, it is well known that cancer-signaling pathways play pivotal roles in the 
biologic behavior of tumor cells that creates an opportunity to rethink cancer in 
general [13] and rethink cancer targeting strategies with small molecules [14, 15], 
with monoclonal antibodies [16] and induced antibodies [17, 18]. By the same 
token such pathways are also involved in developing therapeutic resistance, which 
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Chapter 3




While the interest in cancer vaccines is renewed by some results in vaccine-
based clinical trials, the premise still suffers from the incomplete concept of a 
successful vaccine. Future progress may come from matching preclinical data with 
clinical expectations while taking a step back to understand the systems perspec-
tive. A field that benefits most from this bird’s eye view is tumor immunology. For 
instance, the accumulation over the last three decades of clear associations of T and 
B cell cross-reactivity between a set of host targets of autoimmunity and microbial 
antigens strongly supports a pathogenic role for molecular mimicry. Mimicry on its 
turn invites the concept of networks of molecular interactions. The intentional and 
rational approach to exploit mimicry in cancer vaccine development, while littered 
with failure, has provided also some insight into success. Here, we visit successes 
and underlying rationale to lend to future development of mimetic vaccines in 
immune-oncology.
Keywords: vaccine, anti-idiotype, peptide, tumor associated carbohydrate antigens, 
carbohydrate mimetic peptide
1. Introduction
Targeting malignancies through manipulating the immune system has seen 
success in a variety approaches ranging from whole cell vaccination, to autologous 
dendritic cell based vaccines and therapeutic immune-modulation [1–5]. But a 
number of opportunities and challenges remain. While tumor antigen identification 
from sequencing the cancer genome continues to be a high priority we now know 
that tumor antigens arise from multiple mechanisms that include somatic muta-
tions, translocations, and amplifications and post-translational modifications. The 
role of post-translational modification with tumor associated carbohydrate antigens 
(TACA) in the generation of novel cancer antigens is in particular an opportunity to 
be explored [6–9].
Characterizing and overcoming the immunosuppressive environment of the 
tumors has led to a focus on downstream checkpoints that regulate activated T cells, 
or on vaccination and T cell adoptive transfer to expand the T cell pool [10–12]. 
However, it is well known that cancer-signaling pathways play pivotal roles in the 
biologic behavior of tumor cells that creates an opportunity to rethink cancer in 
general [13] and rethink cancer targeting strategies with small molecules [14, 15], 
with monoclonal antibodies [16] and induced antibodies [17, 18]. By the same 
token such pathways are also involved in developing therapeutic resistance, which 
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requires alternative immunotherapeutic strategies. One such strategy is to develop 
polyclonal humoral immune responses by active immunotherapy. Itself, this 
concept can have multiple approaches and an orchestra of potential mechanisms 
that encompass a dynamic systems immunology perspective (Figure 1). On the one 
hand the effect can be pursued by formulating a platform with multiple epitopes 
of target antigens [19]. On the other—making use of polyspecific (pan-antigen) 
mimetics to target simultaneously multiple antigens on cancer cells [17, 18]. A 
polyclonal antibody approach would target more than two antigens on a single 
tumor cell, which is expected to have even higher potential. This latter idea is a part 
of the conceptual evolution in immune-oncology harnessing polyclonal responses 
to cancer cells.
2. Setting the stage: systems concepts
Systems immunology is now in focus to understand the immune system [20], 
especially in the context of vaccinology [21]. This perspective is ushering in a 
new era in vaccine development [22]. For the future, it is argued that successful 
approaches will depend on the elucidation of the entire network of immune sig-
naling pathways that regulate immune responses with an eye toward integrating 
advances in computational and systems biology, genomics, immune monitoring, 
bioinformatics and machine learning [22, 23].
Systems immunology also teaches us that one antigen can substitute for another 
having the potential to regulate tolerance [24–28]. However, it is unclear why an 
immune system that is tolerant of its own self-antigens would respond to a self-anti-
gen mimic in a vaccine. Antibodies referred to as anti-idiotypic are produced during 
Figure 1. 
The concept of mimetic vaccines in oncology. On the one end the spectrum of B cell subsets includes high 
affinity/specificity clones generated by somatic hypermutation in B2 follicular cells under conditions of strict 
tolerance to self. On the other, are the innate like B1a cells producing constitutively poly/autospecific natural 
antibodies. Carbohydrate specificity and anti-idiotype interactions are related more to the later compartment. 
Polyspecific vaccines based on carbohydrate mimotopes or idiotypes recruit B cell clones across that spectrum but 
their novel properties are related mostly to their capacity to elicit diversified responses from MZ and B1 cells 
including idiotypically connected clones. In addition, the mimotopes capture only the most salient features of the 
carbohydrate epitopes and induce diversified responses targeting multiple antigens (illustrated by diverse words 
sharing only partially the topology of the mimotope as compared to highly specific responses that match the 
shape of the epitope). Thus, mimetic vaccines both target polyspecific compartments of the B cell repertoire as 
well as they themselves function as polyspecific antigens.
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the process of tolerization and demonstrated in tolerant animals [29, 30] and in 
patients [31]. These antibodies may prevent a B cell receptor from interacting with 
the antigen. Jerne envisioned the immune system as a web of immunoglobulin V 
domains constituting an idiotypic network. Inherent to the idiotype network is that 
antibodies recognize antibodies. Jerne thought that regulatory processes governed 
by idiotypic interactions could explain the generation of the various immune states 
that include tolerance.
An extension of the network theory was that antibodies, by virtue of being recog-
nized by antibodies, might function as mimics of antigens that would break tolerance 
instead of maintaining it—the so-called Ab2, used as antigen surrogates [32]. Thus a 
new context of molecular mimicry was born—one highlighted by the functionality 
of idiotypic antibodies in the context of the idiotype network theory [33–39].
Smaller fragments (peptides) of anti-idiotypes proved to translate successfully 
to vaccines too [40]. Peptides as mimics of antigens were clearly defined with the 
advent of phage screening technology [41, 42] growing in its application in bio-
medical sciences [43]. Peptide mimics are well defined as B and T cell epitopes [44]. 
Now there is an unprecedented opportunity to unravel the intricacies of the human 
immune response to immunization. Yet, fundamentally, vaccine strategies across 
susceptible disease depend on the identification of immunogenic antigens that can 
serve as the best targets [45–47].
Tumor antigens present a special challenge. Except for small details defined 
by mutations or altered post-translational modifications, generally they are self-
antigens and this poses a barrier to effective vaccination. Tolerance is different 
from non-specific immunosuppression, and immunodeficiency. Like immune 
response, tolerance is specific existing both for T-cell and B cells and, like immuno-
logical memory tolerance is lasting longer at the T cell level than at the B cell level. 
Maintenance of immunological tolerance requires persistence of antigen. Tolerance 
can be broken naturally or artificially [48, 49]. Mimicry might impact on an already 
existing autoimmune process rather than precipitate novel disease by breaking of 
tolerance from the beginning [50]. While molecular mimicry is proposed as a basis 
for potential pathogenesis of some human disease, there are examples also of its 
exploitation in vaccine development.
3. Polyclonal activation
Now it is acknowledged that the natural antibody repertoire is created in the 
absence of exogenous antigens and/or germinal center maturation [51, 52]. It is also 
acknowledged that these preexisting antibodies can be affected by the presence 
of exogenous antigen since they recognize in a polyspecific manner evolutionarily 
fixed epitopes present in foreign antigens as well as on self-antigens [53]. Because 
of their constitutive expression, responses by natural antibodies are generally 
excluded from vaccine strategies. Among approaches that can modulate the natural 
antibody repertoire are immunizations affecting idiotypic interactions. When pos-
sible, an “idiotypic vaccination” could be a little explored way to activate the B and 
T cell cascades involving the natural responses against antigens.
Once acclaimed, idiotypy—the theory that the B lymphocyte repertoire forms a 
highly connected network of mutually recognizing and stimulating clones  
[54, 55]—unfortunately predated the discovery of many more levels of immune 
system complexity. The daunting task of attuning to the new knowledge prevented 
this theory from maintaining a support that would match its intellectual attractive-
ness. The first significant update, which almost rehabilitated it, stated that only the 
compartment of the B cell repertoire characterized by germline variable regions and 
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the process of tolerization and demonstrated in tolerant animals [29, 30] and in 
patients [31]. These antibodies may prevent a B cell receptor from interacting with 
the antigen. Jerne envisioned the immune system as a web of immunoglobulin V 
domains constituting an idiotypic network. Inherent to the idiotype network is that 
antibodies recognize antibodies. Jerne thought that regulatory processes governed 
by idiotypic interactions could explain the generation of the various immune states 
that include tolerance.
An extension of the network theory was that antibodies, by virtue of being recog-
nized by antibodies, might function as mimics of antigens that would break tolerance 
instead of maintaining it—the so-called Ab2, used as antigen surrogates [32]. Thus a 
new context of molecular mimicry was born—one highlighted by the functionality 
of idiotypic antibodies in the context of the idiotype network theory [33–39].
Smaller fragments (peptides) of anti-idiotypes proved to translate successfully 
to vaccines too [40]. Peptides as mimics of antigens were clearly defined with the 
advent of phage screening technology [41, 42] growing in its application in bio-
medical sciences [43]. Peptide mimics are well defined as B and T cell epitopes [44]. 
Now there is an unprecedented opportunity to unravel the intricacies of the human 
immune response to immunization. Yet, fundamentally, vaccine strategies across 
susceptible disease depend on the identification of immunogenic antigens that can 
serve as the best targets [45–47].
Tumor antigens present a special challenge. Except for small details defined 
by mutations or altered post-translational modifications, generally they are self-
antigens and this poses a barrier to effective vaccination. Tolerance is different 
from non-specific immunosuppression, and immunodeficiency. Like immune 
response, tolerance is specific existing both for T-cell and B cells and, like immuno-
logical memory tolerance is lasting longer at the T cell level than at the B cell level. 
Maintenance of immunological tolerance requires persistence of antigen. Tolerance 
can be broken naturally or artificially [48, 49]. Mimicry might impact on an already 
existing autoimmune process rather than precipitate novel disease by breaking of 
tolerance from the beginning [50]. While molecular mimicry is proposed as a basis 
for potential pathogenesis of some human disease, there are examples also of its 
exploitation in vaccine development.
3. Polyclonal activation
Now it is acknowledged that the natural antibody repertoire is created in the 
absence of exogenous antigens and/or germinal center maturation [51, 52]. It is also 
acknowledged that these preexisting antibodies can be affected by the presence 
of exogenous antigen since they recognize in a polyspecific manner evolutionarily 
fixed epitopes present in foreign antigens as well as on self-antigens [53]. Because 
of their constitutive expression, responses by natural antibodies are generally 
excluded from vaccine strategies. Among approaches that can modulate the natural 
antibody repertoire are immunizations affecting idiotypic interactions. When pos-
sible, an “idiotypic vaccination” could be a little explored way to activate the B and 
T cell cascades involving the natural responses against antigens.
Once acclaimed, idiotypy—the theory that the B lymphocyte repertoire forms a 
highly connected network of mutually recognizing and stimulating clones  
[54, 55]—unfortunately predated the discovery of many more levels of immune 
system complexity. The daunting task of attuning to the new knowledge prevented 
this theory from maintaining a support that would match its intellectual attractive-
ness. The first significant update, which almost rehabilitated it, stated that only the 
compartment of the B cell repertoire characterized by germline variable regions and 
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the prerequisite physiological poly/autoreactivity forms this network [56]. Almost, 
because many immune system phenomena like a self-assertive rather than ignorant 
tolerance or the immune memory ultimately do not need to be explained by emer-
gent properties of the immune network. Now it is accepted that specific cell popula-
tions and genetic programs rather than the dynamics of a network of functionally 
equivalent agents (clones) are responsible for almost all of the observed immune 
phenomena. In fact, recent development in our understanding of swarms of simple 
agents uncovers the limits of such systems where complexity of the behavior of the 
agents and the size of the system have Goldilocks conditions for optimal behavior 
[57]. No wonder, evolution has used the “swarm” solution rarely and ultimately 
replaced it (complemented it) in most cases by centralized systems and specialized 
components at a higher level of organization.
Another reason the intellectually attractive “second generation network” 
hypothesis also fails is may be the fact that the compartment producing natural 
antibodies is defined in many ways and even 25 years later is still rather a fuzzy 
set [53]. While the natural antibodies in a strict sense are produced by a particular 
subset of B1 cell derived plasma cells in the bone marrow without external stimulus 
there are B1 cells (e.g. B1b) and marginal zone cells that produce antibodies with 
many “natural” characteristics like polyspecificity in response to stimulation [58]. 
Thus, focusing on the naturally autoreactive compartment of the repertoire did not 
answer all questions but also added another dimension of uncertainty.
Natural antibodies are known to bind to a variety of antigens that are both self 
and exogenous and thereby providing one of the first lines of defense against both 
bacterial and viral pathogens [53, 59]. Antibodies reactive to self-antigens play a key 
role in both healthy individuals and patients with autoimmune disorders [60–62]. 
Hence, such antibodies are intrinsically multifaceted in their regulatory roles in 
immune responses and tolerance. While the immune response activated against self 
can be detrimental when triggered in an autoimmune genetic background, tuning 
immune activity with natural antibodies is a potential therapeutic strategy. One 
conceptual approach in this tuning is using naturally occurring anti-idiotype (anti-
Id) antibodies to stimulate multifaceted natural antibodies.
4. Anti-idiotypic antibodies as mimics
Anti-idiotypic based vaccines have a long history of generating immune 
responses in experimental animals and in humans [27, 28, 63–65]. One of the first 
demonstrations for the basis of molecular mimicry observed between proteins and 
anti-idiotypes for proteins was dissected in the TEPC-15 idiotype system [66]. Vasta 
et al. [66] illustrated that mimicry could be at the sequence level. They suggested 
that the minimal stretch of homology (8–10 amino acid residues) was responsible 
for the cross-reactive nature of the TEPC-15 idiotype and the acute-phase protein 
C-reactive protein (CRP) from the horseshoe crab Limulus polyphemus (limulin). 
Of no less importance, it was shown that T helper cells could recognize a shared 
determinant that is present on idiotypically different myeloma proteins [67]. These 
findings collectively showed that T helper cells, induced by priming with antigen, 
can recognize shared idiotypic determinates, suggesting that peptides derived from 
anti-idiotypes can be processed as immunogens [40, 68].
The early studies of anti-idiotypes made clear the idea that functional mimicry 
of ligands of biological receptors is a matter of just binding to an antibody-binding 
site. This functional or antigenic mimicry ushered in concepts and a technology. It 
was evident that structural and immunological rules governing molecular mimicry 
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require definition for its successful exploitation whether anti-idiotypes, small frag-
ments derived from them or peptide mimetics [69, 70]. It was suggested that ligand-
based pharmacophore design principles could be applied to designing peptides that 
can mimic ligands reactive with antibodies [69, 71]. Often times it was stated that 
there were no observable structural correlations to explain the mimicry [72]. Yet 
it seemed that antibodies could mimic antigens at the molecular level whereby the 
antigen and anti-idiotype could bind essentially the same combining-site residues 
of the Ab1 antibody [73].
Historically, clinical trials with anti-idiotypes in the cancer space have proved 
to be of mixed success [74, 75] but, clearly showing that humoral and cellular 
immune reactivity against a tumor can be enhanced upon active anti-id vaccination 
[76]. Other studies with anti-ids in humans have included those associated with 
tumor associated carbohydrate antigens (TACAs), [77–80]. An anti-Id vaccine, 
Racotumomab, raised against the murine anti-ganglioside N-glycolyl (NGc) GM3 
(NGcGM3) has shown efficacy [81] in several phase I trials in melanoma, breast 
and lung cancers [82, 83]. These examples are representative for other anti-Id 
vaccine trials. In sum they indicate the induction of B and T-cell immune responses 
against a tumor.
5. Mimetic peptides in immuno-oncology
From a technology perspective the concept of developing and screening com-
binatorial or random peptide phage display became an effective means of identify-
ing peptides that can bind target molecules and regulate their function [41, 42]. 
Phage-displayed peptide libraries have proved effective for (i) mapping of B and T 
cells epitopes, (ii) defining bioactive peptides that bind to receptors, (iii) selection 
of cell/organ specific binding peptides, and (iv) identification and development of 
peptide-mediated drug delivery systems to mention a few applications [43]. Among 
concepts emphasized by phage screening technology was that of the mimotope. The 
term mimotope, coined by Mario Geysen in 1986 [84] described a peptide mimick-
ing a discontinuous antigenic determinant on foot and mouth virus. Phage screen-
ing technology has evolved, giving us unparalleled access to tight binding peptides 
to significantly accelerate identification of new leads for drug discovery [85].
The ability to produce combinatorial peptide libraries with a highly diverse pool 
of randomized ligands has transformed phage display into a straightforward, versa-
tile and high throughput screening methodology for the identification of potential 
vaccine candidates against different diseases that include cancer [86–88]. While 
most studies with mimotopes identified by phage screening are still in preclinical 
studies, immunization results do provide insight for future development of novel 
mimotope-based tumor vaccines [89–92]. Starting from phage screening, we have 
developed carbohydrate-mimetic peptide (CMP) vaccines that target carbohydrate 
antigens [70, 71]. We brought CMPs from preclinical assessments of mimicking 
peptides of TACA [93–95] to clinical studies [17, 18] where one peptide can induce 
polyclonal responses to two or more antigens, which do or do not share epitopes.
Clinically we have shown that CMPs can achieve this multi-epitope target-
ing. The peptide P10s is a CMP designed to mimic both LeY and GD2 antigens 
using anti-LeY (BR55-2) and anti-GD2 (ME36.1) antibodies as templates [95]. 
Therefore, vaccination with P10s may lead to targeting various molecular enti-
ties associated with glycoproteins and with glycolipids, reducing the possibility 
of immune editing and escape. Moreover, the P10s vaccine has the potential to 
activate cellular responses [96]. We completed a phase I clinical trial of the P10s 
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vaccine in breast cancer patients and showed its feasibility, safety and immune 
efficacy. The data indicates induction of anti-peptide and anti-glycan antibod-
ies [17, 18]. Antibodies of immunized subjects mediated cytotoxicity on human 
breast cancer cell lines through currently unknown mechanisms independent 
of complement-mediated cell cytotoxicity, but had no effect on normal breast 
cell line MCF-10A [17, 18]. Serum antibodies parallel the effect of anti-LeY and 
anti-GD2 monoclonal antibodies. After more than 6 years of follow up, 4 out of 
6 vaccinated subjects are still alive with 3 of them in remission. Our clinical data 
suggest that vaccination of breast cancer patient’s results in tumor regression and 
survival benefit.
6. Linking signaling with polyclonal response
The complexity of glycans found on the cell surface argues for their informa-
tional role involved in regulating multiple cellular processes essential for tumor 
development or its metastases. Since TACAs are expressed on glycoproteins and 
glycolipids that regulate multiple cellular pathways, TACAs are by definition 
pan-targets. Many glycoproteins and glycolipids are associated with signaling 
cascades through Focal Adhesion Kinase (FAK) with its activation hypothesized 
to play an important role in the pathogenesis of human cancers [97, 98]. FAK is a 
non-receptor tyrosine kinase that plays an important role in signal transduction 
pathways that are initiated at sites of integrin-mediated cell adhesion and by growth 
factor receptors [99]. FAK is also linked to oncogenes at both a biochemical and 
functional level. Moreover, overexpression and/or increased activity of FAK are 
common in a wide variety of human cancers, implicating a role for FAK in carci-
nogenesis. It is therefore a key regulator of survival, proliferation, migration and 
invasion: signaling cascades and processes that are all involved in the development 
and progression of cancer. FAK localized at focal contact sites and communicates 
with TACA-expressing molecules. Coordinated and localized stimulation of these 
cascades influences focal contact turnover and actin cytoskeleton dynamic addition 
to expression of motility- and invasion-associated proteins such as matrix metallo-
proteinases. FAK-dependent regulation of chemokine’s and cytokines in cancer cells 
can drive elevated levels of regulatory T cells into the tumor environment resulting 
in suppression of the anti-tumor CD8+ T-cell response [100].
FAK is associated with several mechanisms to regulate cell migration and 
invasion through its phosphorylation. These include interactions with Src, P13K, 
Grb7, N-WASP and EndoII. Interaction with integrin also mediates FAK association 
with extracellular matrix, triggering the binding of adaptor molecules leading to 
the modulation of small GTPases, Ack, ERK2/MAP and JNK/SAP kinase cascades. 
The convergence of signaling by FAK plays an important role in tumor-cell survival 
and in drug resistance, as these pathways overlap. Given the important role of FAK 
in a large number of processes involved in tumorigenesis, metastasis, and survival 
signaling, Akt/FAK pathways are now regarded as a potential target to overcome 
drug resistance.
A variety of results suggest that GD2 and LeY play a role in the migration and 
survival of cancer cells, since (i) anti-GD2 antibodies [101] and natural anti-TACA 
antibodies [102] can mediate anoikis; (ii) apoptosis signals are transduced via 
reduction in the phosphorylation levels of FAK, the activation of a MAPK family 
members, p38 and c-Jun terminal kinase (JNK), upon binding of such antibodies 
[101, 103]; (iii) P10s reacts with anti-GD2 and anti-LeY monoclonal antibodies; 
(iv) anti-P10s antibodies block cell migration and (v) anti-P10s antibodies from 
P10s immunized subjects are cytotoxic to human breast cancer cell lines.
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7. Synergism of chemo- and immunotherapy
Combining agents with distinct or perhaps overlapping mechanisms of action 
can potentially result in synergistic anticancer effects. Numerous preclinical 
studies have established the synergistic relationships between modulation of Tregs 
and differential expression of immune effector ligands on tumor cells [104, 105]. 
Consequently, combinatorial anticancer therapy is now a well-established paradigm 
due to a number of clinical trials demonstrating therapeutic success. However, the 
mechanisms associated with successful application are not well understood [106]. 
Standard cancer chemotherapy can promote tumor immunity in two major ways: 
(i) inducing immunogenic cell death as part of its intended therapeutic effect lead-
ing to epitope spreading [107, 108]; and (ii) disrupting strategies that tumors use 
to evade the immune response [109, 110]. In particular, epitope spreading ensures 
a polyclonal, polyfunctional immune response that promises to keep the tumor in 
check indefinitely [111]. Cancer patients can display tumor-reactive antibodies at 
baseline, which can increase in both breadth and quantity after immunotherapy 
[112]. IgG antibodies, produced by B cells, are indicative of CD4 helper T cells of 
linked specificity. Activation of tumor-specific CD8 T cells result from the same 
processes that generate activated CD4 T cells.
Checkpoint inhibitors have changed the face of immunotherapy with objective 
responses observed in some patients based on combinatorial regimes involving 
CTLA4 agent ipilimumab and the PD-1-specific checkpoint inhibitor nivolumab 
[113]. Nevertheless, a sizeable fraction of patients do not respond to checkpoint 
inhibitor combination. This could be for several reasons that include but are not 
limited to not having the correct T cell precursors to target the tumor associated 
antigens, dysfunctional T cell receptors and down regulation of MHC complexes 
[114, 115]. Interestingly, FAK inhibition has been noted to increase the activity 
of checkpoint inhibitors [116]. This work suggests that FAK inhibition increases 
immune surveillance and renders tumors responsive to immunotherapy.
In our own work when combining chemotherapy with CMPs we primarily 
focused on immune effector synergistic relationships. A particular synergistic 
action requires apoptotic tumor cell death, and does not occur as a consequence 
of perturbations in immunological regulatory circuits. The resistance of many 
types of cancer to conventional chemotherapies is problematic and a major factor 
undermining successful cancer treatment. Again FAK plays a role with its silencing 
augments docetaxel-mediated apoptosis of cancer cells [117]. We have shown that 
immunization with P10s can overcome resistance to taxanes and coupled with other 
studies indicating that targeting GD2 antigen is associated with FAK silencing we 
have come to another important therapeutic option of inducing multiple responses 
that go through the FAK gatekeeper to improve upon immunotherapy strategies.
8. Conclusion
Harnessing the body’s own immune system to kill cancer cells has shown prom-
ise for a growing number of cancers, revolutionizing the clinical management of 
multiple tumors. The success of checkpoint antagonists heralds the dawn of a new 
age in cancer therapy, in which immunotherapy is becoming a key strategy for clini-
cal management. Checkpoint inhibitors have taught us that they can unleash natural 
responses to tumor cells. The goal of cancer vaccines should be rethought in terms 
of boosting those natural responses. Combination therapies that integrate distinct 
therapeutic modalities that include vaccines, small molecules, radiotherapy and 
checkpoint inhibitors are under investigation. Yet understanding the cellular and 
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molecular underpins are essential for effective translation to the clinic. Polyclonal 
activation of the immune system should lend to epitope spreading phenomena, 
which will further effectiveness of cancer therapy. Yet this concept had been for the 
most part limited to the idea of presenting multiple epitopes of a particular target 
associated with T cell activation. This viewpoint needs to be reassessed to include 
the idea of extending to humoral responses since antibodies have proved to be 
essential to the cancer treating armament.
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Natural Killer (NK) Cell 
Alloreactivities against Leukemic 
Cells: Functions beyond Defense
Suwit Chaisri and Chanvit Leelayuwat
Abstract
Immunotherapy using adoptive transfer of natural killer (NK) cells has progres-
sively been utilized in hematologic malignancies over the past decade. Presently, NK 
cell immunotherapy has been promising and feasible in acute leukemia, particularly 
in acute myeloblastic leukemia (AML). Alloreactive NK cells have been exploited 
under the killer immunoglobulin-like receptor (KIR)-ligand mismatches between 
donors and recipients in haploidentical hematopoietic stem cell transplantation 
(haplo-HSCT) after immunosuppressive chemotherapy. Of interest, alloreactive 
NK cells killed residual leukemic cells, dendritic cells (DCs) and T cells in acute leu-
kemia patients and led to significantly improved clinical outcomes. Consequently, 
this chapter provides the KIR genetics and the mechanisms of alloreactive NK cells 
that are shown to be crucial in the successful therapy of acute leukemia (myeloid 
and lymphoid). Altogether, the donor selection algorithm of haplo-HSCT is 
discussed to emphasize the importance and give priority to increase the chances 
of therapy success. These will be useful for students and researchers who work 
in immunogenetics. Furthermore, the knowledge would be applicable to clinical 
research and medical sciences.
Keywords: NK cell alloreactivity, KIR polymorphisms, KIR-ligands mismatch,  
acute leukemia, haploidentical HSCT
1. Introduction
Natural killer (NK) cells play a critical role in innate immune responses against 
infected cells and transformed cells. In the past decades, the molecular mechanisms 
of NK cell killings have been extensively elucidated as well as employed in clini-
cal applications [1, 2]. The effector functions of NK cells are being investigated 
in several pathological conditions, particularly in cancers [3, 4]. Many researches 
highlight on the role of NK cells in hematologic malignancies, particularly in acute 
leukemia. Acute leukemia is a type of cancer in which the bone marrow produces 
too many immature white blood cells and they cannot carry out normal functions. 
In addition, leukemic cells crowd out all blood cell productions in the bone mar-
row, affecting normal blood functions and leading to serious health problems. The 
treatment options for acute leukemia include chemotherapy, radiotherapy and bone 
marrow (hematopoietic stem cell) transplantation. Considering HLA matching 
between donors and patients for hematopoietic stem cell transplantation (HSCT), 
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the patient’s outcomes are related with a closely matched donor, however, not all 
patients are able to find a suitable donor. To overcome the limitations of donor 
availability, a partially matched or haploidentical HSCT (haplo-HSCT) has been 
established as an alternative expedient and being a mode of curative therapy for 
hematologic malignancies [5], particularly in acute leukemia patients [6]. In addi-
tion, a complication of allogeneic HSCT has improved with graft versus host disease 
(GvHD) prophylaxis to prevent the effects of donor T cells. Evidently, the role of 
NK cell alloreactivity can significantly improve clinical outcomes in acute leukemia 
patients [7]. Among NK cell receptors, killer immunoglobulin-like receptor (KIR) 
has increasingly been exploited in the aspect of immunotherapy for acute leuke-
mia, which mismatches between KIR on donor NK cells and their cognate ligand 
HLA class I on receipts lead to alloreactivity of NK cells in haplo-HSCT setting. 
Alloreactive NK cells exert powerful activity in killing residual leukemic cells, lead-
ing to preventing disease relapse and improving survival [7, 8]. With these reasons, 
NK cell alloreactivities mediated by KIR-ligand mismatches has been increasingly 
utilized in aspect of immunotherapy for clinical applications. Therefore, this 
chapter provides KIR genetics and KIR-mediated NK cell alloreactivities that have 
been shown to be crucial in the successful therapy of acute leukemia (myeloid and 
lymphoid). Additionally, donor selection algorithm of haploidentical HSCT mis-
match is discussed to emphasize its role in increasing success rate of these therapies.
2. Natural killer (NK) cells
NK cells are considered a part of lymphocytes that account for approximately 
10% of blood lymphocytes. NK cells are characterized by expression of CD56 
surface antigen and a lack of CD3 antigen. Based on the density of CD56 expres-
sion, human NK cells are phenotypically divided into two groups: CD56bright and 
CD56dim. Of these NK cell populations, CD56dim NK cells represent up to 90% of 
NK cells in human peripheral blood mononuclear cells (PBMCs) and are considered 
the most cytotoxic subset, while CD 56bright NK cells comprise approximately 10% 
of NK cells in PBMCs and are known as the cytokine-producing subset. NK cells 
play important role of the first line of defense to infected cells and transformed cells 
without prior sensitization [9, 10]. Several receptors present on NK cells are cur-
rently identified, however, they are classified into two groups depended on signal 
transductions derived from those receptors, namely activating and inhibitory receptors 
[11] (Table 1). Importantly, the dynamic equilibrium of signals obtained by these 
receptors is important to determine whether NK cells are activated to kill target cells 
[12, 13]. The missing self-hypothesis has been proposed to explain whether NK cells 
discriminate target cells form healthy “self” cells by their various receptors [14]. 
Normally, engagement of inhibitory receptors by self MHC class I molecule leads 
to transmission of an inhibitory signal to switch off the NK cell functions, while 
down-regulated MHC molecules on target cells by viral infection or malignant 
transformation is recognized and attacked by NK cells. Cytotoxicity and cytokine 
secretion of NK cells depended on the interaction between their receptors and 
their corresponding ligands. Activated NK cells usually exert cytotoxic activity 
through three main pathways. Firstly, the perforin/granzymes pathway, activated 
NK cells release these molecules to intracellular space. The perforin directly forms 
a transmembrane channel on the target cell, leading to increased permeability of 
the target cell membrane and causing osmotic lyses of target cells. In addition, 
granzymes enter the cytoplasm of target cells through transmembrane pores to 
promote target cells apoptosis [15]. Secondly, the Fas/FasL pathway, when Fas on 
NK cells binds to FasL on the target cells, Fas derivers a death signal to the target cell 
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and they undergo apoptosis [16, 17]. Lastly, the cytokine pathway, NK cells secrete 
various cytokines, such as IFN-γ, TNF-α, GM-CSF and IL-10. These cytokines play 
an important role in immune responses of NK cells. For example, TNF-α alters the 
stability of lysosome in target cells, resulting in leakage of various hydrolases, effect 
on metabolism of cell membrane phospholipid and degradation of genomic DNA by 
endonuclease [18]. With these mechanisms, applications of NK cells have currently 
been established in tumor immunotherapy as chimeric antigen receptor-modified 
NK cells (CAR-NK cells) and adoptive immunotherapy.
3.  Killer immunoglobulin-like receptor (KIR) polymorphisms mediated-
heterogeneity of NK cell responses
Killer immunoglobulin-like receptors (KIRs) are cell surface receptors expressed 
on NK cells and subpopulation of T cells. Similar to HLA class I, KIR ligands, KIRs 
are highly polymorphic genes, including allelic polymorphisms, genes content and 
copy number variations [19]. Genetic variations of KIRs and HLA among individuals 
generate heterogeneity of immune responses of NK cells [20]. Interestingly, current 
evidences demonstrate the impact of KIR gene variations on disease susceptibility 
or resistance in several pathological conditions, such as infection, autoimmune/
inflammatory disorder, implantation and particularly in hematopoietic stem cell 










KIR-L HLA-A, -B, -C
LAIR-1 Collagen
LILRB1 HLA-A, -B, -C
NKR LLT-1
KLRG1 Cadherins
SIGLEC3, 7,9 Sialic acid
CD94-NKG2A HLA-E
Activating or inhibitory receptors
KIR2DL4 HLA-G?
KIR-S: killer cell immunoglobulin-like receptor with short cytoplasmic tail; KIR-L: killer cell immunoglobulin-
like receptor with long cytoplasmic tail; LAIR-1: leukocyte-associated immunoglobulin-like receptor 1; LILRB1: 
leukocyte immunoglobulin-like receptor B1; KLR: killer cell lectin-like receptor; NKR: NK cell receptor; SIGLEC: 
sialic acid-binding immunoglobulin-type lectins; HLA: human leukocyte antigen; LLT: lectin-like transcript 1. 
IgG: immunoglobulin G; BAT3: leukocyte antigen-B-associated transcript 3; MIC: MHC class I-related chain 
family; ULBP: UL16-binding proteins; HLA-G?: It is controversial whether HLA-G is a lignad of KIR2DL4.
Table 1. 
NK cell receptors and their cognate ligands.
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transplantation [21]. Here, to better understand the role of NK cell alloreactivities, 
we thoroughly describe the basis of KIRs as well as its role in the immune system.
3.1 Killer immunoglobulin-like receptors (KIRs, CD158)
Killer immunoglobulin-like receptors are type I transmembrane glycoprotein 
expressed on the plasma membrane of NK cells, subpopulations of memory T cells 
and most of CD8+ T cells [22, 23]. The KIR family consists of 15 functional genes 
(KIR2DL1–4, 2DL5A, 2DL5B, 2DS1–5, 3DL1–3, 3DS1) and 2 pseudogenes (2DP1 and 
3DP1) encoded within a 150 kb region of the leukocyte receptor complex (LRC) 
located on chromosome 19 (19q13.4) [24, 25] . The KIR proteins have either two or 
three extracellular immunoglobulin domains (KIR2D or KIR3D) and cytoplasmic 
(CYT) tails with long (L) or short (S) tails. Based on structural feature, a long cyto-
plasmic tail (KIR2DL or KIR3DL) contains immunoreceptor tyrosine-based inhibi-
tory motif (ITIM) that functions to inhibit NK cell responses [26]. In contrast, a 
short cytoplasmic tail (KIR2DS or KIR3DS) has a positive charge amino acid residue 
in the transmembrane region to associate with DAP12 containing an immunorecep-
tor tyrosine-based activating motif (ITAM) that turns on NK cell functions [27]. 
Uniquely, KIR2DL4, a long cytoplasmic tail containing ITIM and linking with an 
adaptor molecule FcεRI, can deliver both activating and inhibitory signals to control 
NK cell responses [28, 29]. However, the mechanism by which KIR2DL4 delivers 
activating or inhibitory signals to NK cells is not established. Two pseudogenes, 
KIR2DP1 and KIR3DP1, are not expressed on NK cells.
3.2 Diversity of KIRs
The extensive variation of KIR loci is achieved through allelic polymorphisms, a 
combination of gene content (absence/presence polymorphisms) and copy number 
variations. Firstly, allelic polymorphisms of KIR have been documented in the 
Immuno Polymorphism Database (IPD) showing each KIR locus contains 16–164 
alleles of different genes [30]. Later, a combination of genes content generates 
distinct KIR genotypes, showing 625 different KIR genotypes reported in 171 popu-
lations worldwide [31]. Lastly, copy number variation (CNV) of KIR is currently 
studied and demonstrated that equal and unequal crossing over generates indi-
vidual KIR gene duplication, deletion and hybridization [32]. Moreover, stochastic 
and variegated KIR expressions on NK cells by epigenetic regulation facilitate 
a diverse repertoire of NK cell clones within an individual [33] (Figure 1). As a 
consequence, the influence of KIR diversity on immune responses has been reported 
in several diseases [21, 34–36]. On the basis of gene content, KIRs are classified into 
group A and B haplotypes [37]. Both group A and B haplotypes are conserved with 
four framework genes (KIR3DL3-3DP1-2DL4-3DL2). Group A haplotype consists 
of the four framework genes and 2DL3, 2DP1, 2DL1, 3DL1 or 2DS4, whereas group 
B haplotype has variable gene content. Distinctly, group A haplotype shows pre-
dominantly inhibitory KIR genes except KIR2DS4, but group B haplotype contains 
dominantly activating KIR genes. The distributions of KIR haplotypes have been 
studied, showing variations of A and B are found among populations [38–43].
3.3 KIR and their cognate ligands
Both inhibitory and activating KIRs on NK cells recognize HLA class I mol-
ecules of target cells. Most KIR ligands have recently characterized as shown in 
Table 2, whereas some KIR ligands are still unknown [44–47]. The affinity of KIR 
and HLA interaction affects NK cell responses [48]. Remarkably, activating KIRs 
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(KIR2DS1/2) and inhibitory KIRs (KIR2DL1/2) can bind the same HLA molecules. 
However, the affinity of inhibitory KIR-binding HLA is higher than activating KIR-
binding HLA [49, 50]. It is believed that the lower affinity of activating KIR and 
HLA interaction would be evolved to avoid self-aggression.
4.  Alloreactive NK cells from transplantation to adoptive 
immunotherapy
Over the past decade, adoptive transfer allogeneic NK cells have been emerged 
as promising immunotherapy for hematological malignancies [8, 51, 52]. The role 
of alloreactive NK cells is considered to be beneficial in achieving better outcomes 
KIR KIR ligand (HLA) Function
2DL1 HLA-C2 (HLA-CLys80) Inhibition
2DL2 HLA-C1 (HLA-CAns80) Inhibition
2DL3 HLA-C1, HLA-C2 (weak) Inhibition
2DL4 HLA-G?* Activation/inhibition?
2DL5 Unknown Inhibition
2DS1 HLA-C2 (HLA-CLys80) Activation
2DS2 HLA-C1 (HLA-CAns80), β2-Microglobulin Activation
2DS3 Unknown Activation
2DS4 HLA-A11 and some HLA-C alleles Activation
2DS5 Unknown Inhibition
3DL1 HLA-Bw4 Inhibition
3DL2 HLA-A3, -A11 Inhibition
3DL3 Unknown Inhibition
3DS1 HLA-Bw4? Activation
*The ligand for KIR2DL4 is still controversy [44, 45].
Table 2. 
KIR and their ligands (HLA) specificity.
Figure 1. 
NK cell repertoires. Individual KIR genotype generates a diverse repertoire of NK cells by stochastic expression. 
KIR expression on NK cells is influenced by HLA class I and CD94:NKG2A.
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transplantation [21]. Here, to better understand the role of NK cell alloreactivities, 
we thoroughly describe the basis of KIRs as well as its role in the immune system.
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ecules of target cells. Most KIR ligands have recently characterized as shown in 
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4.  Alloreactive NK cells from transplantation to adoptive 
immunotherapy
Over the past decade, adoptive transfer allogeneic NK cells have been emerged 
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of alloreactive NK cells is considered to be beneficial in achieving better outcomes 
KIR KIR ligand (HLA) Function
2DL1 HLA-C2 (HLA-CLys80) Inhibition
2DL2 HLA-C1 (HLA-CAns80) Inhibition
2DL3 HLA-C1, HLA-C2 (weak) Inhibition
2DL4 HLA-G?* Activation/inhibition?
2DL5 Unknown Inhibition
2DS1 HLA-C2 (HLA-CLys80) Activation
2DS2 HLA-C1 (HLA-CAns80), β2-Microglobulin Activation
2DS3 Unknown Activation
2DS4 HLA-A11 and some HLA-C alleles Activation
2DS5 Unknown Inhibition
3DL1 HLA-Bw4 Inhibition
3DL2 HLA-A3, -A11 Inhibition
3DL3 Unknown Inhibition
3DS1 HLA-Bw4? Activation
*The ligand for KIR2DL4 is still controversy [44, 45].
Table 2. 
KIR and their ligands (HLA) specificity.
Figure 1. 
NK cell repertoires. Individual KIR genotype generates a diverse repertoire of NK cells by stochastic expression. 
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after haploidentical HSCT (haplo-HSCT). Presently, haplo-HSCT is an alternative 
option when completely matched related or unrelated donors are not available. 
Historically, although haplo-HSCT can lead to graft versus host disease (GvHD) 
which has undesirable effect in post HSCT, this problem has been currently solved 
by performing of T cell depletion before graft infusion. After chemotherapy in 
AML patients, T cell prophylaxis has been used together with high stem cell doses, 
resulting in fast NK cell alloreactivities and slow T cell reconstitution. Moreover, 
graft versus leukemic cells mediated by NK cell, alloreactivities have been exploited 
which they can beneficially lead to reduced relapse, and improve survival [53]. 
Based on the interactions between NK cell receptors and their ligands, it was 
believed that allogeneic NK cells do not receive inhibition signals from the recipient 
HLA, leading NK cells to exert powerful anti-leukemia activity [54]. Regarding 
KIR-ligand mismatches between donor and recipient under haplo HSCT setting, 
alloreactive NK cells play crucial roles against leukemic cells, recipients’ DCs and 
T cells [55], resulting in reduced leukemic relapses, GvHD and graft rejection, 
respectively (Figure 2). With these reasons, a number of studies have extensively 
investigated the role of KIR-ligand mismatches in both pre-clinical and clinical 
setting to evaluate the success in leukemia therapy. Additionally, four situations in 
predicting NK cell alloreactivities after haplo-HSCT have been proposed based on 
the deference in definition of KIR mismatches between the donor NK cells and the 
recipient’s HLA [56] (Figure 3).
4.1 KIR-ligand (HLA) mismatch or missing-self-model
The KIR-ligand mismatch model, also called ligand incompatibility, has been 
proposed that an expression of HLA class I molecules (KIR ligand) on donor are 
Figure 2. 
The role of NK cell alloreactivities in acute leukemia. Beneficial effects of NK cell alloreactivities on the 
outcomes of acute leukemia under haplo-HSCT setting, adoptive transfer NK cells mediated activity against 
residual leukemic cells, recipient’s T cells and dendritic cells, resulting in reduced the risk of relapse, graft 
rejection and GvHD, respectively.
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incompatible with recipient’s HLA class I molecules [57, 58]. This model has been 
assumed that donor NK cells have inhibitory KIR that is missing its ligand on recipi-
ent. For example, NK cells from a HLA-C1/C2 donor will be alloreactive against a 
HLA-C2/C2 recipient, where it is assumed that KIR2DL2 is expressed on donor NK 
cells (Figure 3A).
4.2 Receptor-ligand mismatch model
The receptor-ligand mismatch model states that donor NK cells represent 
inhibitory KIR in mismatching with HLA class I on the recipient target cells, 
Figure 3. 
Situations of NK cell alloreactivity in post-HSCT. (A) The KIR-ligand (HLA) mismatch or missing-self-
model; NK cell alloreactivity is mediated by the lack of HLA ligand expression on recipient for inhibitory 
KIR on donor’s NK cell which the presence of KIR expression on donor is assumed. High resolution HLA 
genotyping is performed in donor and recipient. (B) The receptor-ligand model; NK cell alloreactivity is 
mediated by the lack of HLA ligand expression on recipient for inhibitory KIR which the presence of KIR 
expression on donor NK cell is verified by genotyping and flow cytometry. The donor HLA is irrelevant 
to recipient. (C) The missing-ligand model; NK cell alloreactivity is mediated by the lack of at least one 
of HLA ligand (HLA-C1, -C2 or -Bw4) expression on recipient for inhibitory KIR and the donor HLA 
is irrelevant to recipient. (D) The presence of activating KIR model; NK cell alloreactivity is mediated 
by interaction of activating KIR on donor NK cell and HLA ligand on recipient target cell which KIR B 
haplotype contains more activating KIR than A/A haplotype. KIR genotyping was investigated in donor 
and recipient and some studies detected activating KIR on donor cells.
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respectively (Figure 2). With these reasons, a number of studies have extensively 
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setting to evaluate the success in leukemia therapy. Additionally, four situations in 
predicting NK cell alloreactivities after haplo-HSCT have been proposed based on 
the deference in definition of KIR mismatches between the donor NK cells and the 
recipient’s HLA [56] (Figure 3).
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The KIR-ligand mismatch model, also called ligand incompatibility, has been 
proposed that an expression of HLA class I molecules (KIR ligand) on donor are 
Figure 2. 
The role of NK cell alloreactivities in acute leukemia. Beneficial effects of NK cell alloreactivities on the 
outcomes of acute leukemia under haplo-HSCT setting, adoptive transfer NK cells mediated activity against 
residual leukemic cells, recipient’s T cells and dendritic cells, resulting in reduced the risk of relapse, graft 
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incompatible with recipient’s HLA class I molecules [57, 58]. This model has been 
assumed that donor NK cells have inhibitory KIR that is missing its ligand on recipi-
ent. For example, NK cells from a HLA-C1/C2 donor will be alloreactive against a 
HLA-C2/C2 recipient, where it is assumed that KIR2DL2 is expressed on donor NK 
cells (Figure 3A).
4.2 Receptor-ligand mismatch model
The receptor-ligand mismatch model states that donor NK cells represent 
inhibitory KIR in mismatching with HLA class I on the recipient target cells, 
Figure 3. 
Situations of NK cell alloreactivity in post-HSCT. (A) The KIR-ligand (HLA) mismatch or missing-self-
model; NK cell alloreactivity is mediated by the lack of HLA ligand expression on recipient for inhibitory 
KIR on donor’s NK cell which the presence of KIR expression on donor is assumed. High resolution HLA 
genotyping is performed in donor and recipient. (B) The receptor-ligand model; NK cell alloreactivity is 
mediated by the lack of HLA ligand expression on recipient for inhibitory KIR which the presence of KIR 
expression on donor NK cell is verified by genotyping and flow cytometry. The donor HLA is irrelevant 
to recipient. (C) The missing-ligand model; NK cell alloreactivity is mediated by the lack of at least one 
of HLA ligand (HLA-C1, -C2 or -Bw4) expression on recipient for inhibitory KIR and the donor HLA 
is irrelevant to recipient. (D) The presence of activating KIR model; NK cell alloreactivity is mediated 
by interaction of activating KIR on donor NK cell and HLA ligand on recipient target cell which KIR B 
haplotype contains more activating KIR than A/A haplotype. KIR genotyping was investigated in donor 
and recipient and some studies detected activating KIR on donor cells.
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leading to NK cell alloreactivities in graft versus host direction [59]. This model is 
therefore required for KIR genotyping in donor as well as HLA typing in recipient 
(Figure 3B).
4.3 Missing-ligand model
Notably, the HLA is only genotyped in recipients and missing HLA-C1, C2 
or Bw4 for inhibitory KIR on donor can lead to NK cell alloreactivities [58]. For 
example, recipient represents HLA-C2/C2, therefore, it is assumed (not investi-
gated) that donor NK cells expressing KIR2DL2 to be alloreactive due to missing 
HLA-C1 ligand (Figure 3C).
4.4 Presence of activating KIR model
Here, in this model, activating KIR on donor cells is measured to predict NK 
cell alloreactivities because the interactions between donor activating KIRs and 
their ligands on recipient can lead to NK cells achieving activation signals [60] 
(Figure 3D).
5. The role of NK cell alloreactivities in post HSCT
Several studies have revealed an influence of alloreactive NK cells in acute 
leukemia patients, where alloreactive NK cells deliver promising better outcomes in 
term of anti-leukemia activity. Predominantly, KIR-mediated NK alloreactivity has 
been demonstrated to be the most clinically significant relevance to AML, while its 
role in ALL remains unclear.
5.1 Acute myeloblastic leukemia (AML)
As acute myeloblastic leukemia was more susceptible to NK cell cytotoxicity 
than solid tumors [61], the role of adoptive transfer NK cells against leukemia 
was investigated in AML patients [62]. Anti-leukemic effect of allogeneic NK 
cells has been extensively studied under haplo-HSCT with the mismatches of 
KIR and cognate ligands between donor and recipient. Interestingly, Ruggeri 
and coworkers initially reported allogeneic NK cells mediated cytotoxicity 
against recipients’ leukemic cells [53]. Later, the impact of NK cells allore-
activity in preventing AML relapse, GVHD and rejection was confirmed in 
clinical setting and mouse model [63]. Taken together, this condition has been 
explored under T cell depleted to avoid graft versus host effect and high doses 
of infused stem cell transplantation [54, 63, 64]. Remarkably, this approach was 
investigated in 21 AML children who received haplo-HSCT, showing donor-
derived alloreactive NK cells killed leukemic cells in KIR-ligand mismatches, 
even late after transplantation [7]. Altogether, the doses of infused NK cell and 
immunosuppression were evaluated in children with AML to consider safety 
and effectiveness of alloreactive NK cells therapy [65]. Moreover, successfully 
transferred NK cells immunotherapy were reported in elderly AML who were 
not candidates for HSCT, demonstrating this approach was feasible and safe in 
elderly patients [8, 66].
Haplo-HSCT with KIR-ligand mismatches has been a promising strategy in 
AML for adoptive transfer of NK cells for immunotherapy [67, 68]. The incom-
patibility of three main inhibitory KIR loci (2DL1, 2DL2/3 and 3DL1) with their 
ligands (HLA-C2, HLA-C1 and HLA-Bw4) has been extensively investigated, and 
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found to be relevant for better clinical outcomes [69, 70]. To explain the potential 
benefits of alloreactive NK cells against leukemia based on an absence of inhibi-
tory signal delivered by KIR on donor’s NK cells, it has been shown that KIR2DL1+ 
NK cells lyse leukemia in HLA-C1/C1 recipients, whereas KIR2DL2/3+ NK cells 
partially lyse leukemia in HLA-C2/C2 recipients due to low-affinity binding, and 
that KIR3DL1 + NK cells lyse HLA-Bw4− leukemia of recipients, where HLA-Bw4− 
would be HLA-A or HLA-B as determined by the serotypic specificity. However, 
for the activating KIR model, KIR2DS1+NK cells have demonstrated a potent 
reactivity against HLA-C2 expressing allogeneic target cells in vitro [60, 71], 
particularly on T cells and dendritic cells. As mentioned, although NK cell-based 
immunotherapy has been a promising approach in adult and childhood [8, 65, 
66], there are additional issues that need to be considered in achieving a success-
ful therapy. Firstly, the minimum or optimal number of infused NK cells is really 
required to achieve therapeutic effect that remains inconclusive due to lack of 
standardized technical procedure for qualifying alloreactive NK cells [67, 68].  
Additionally, it became clear that infused NK cells favor IL-2 and IL-15 for expan-
sion and survival [51, 72], however, administration of IL-15 after infusion has 
been recommended because IL-2 can promote host regulatory T cells to inhibit 
allogeneic NK cells.
Given the crucial role of alloreactive NK cells in graft versus leukemia (GVL) 
effect in haplo-HSCT, the predictive algorithm for donor selection is being devel-
oped in AML treatment. Several research groups have explored feasibility of NK 
cell-based immunotherapy, including in vivo and in vitro studies as well as clinical 
trials. Predominantly, mismatches of donors’ inhibitory KIR expressing NK cells 
(2DL1, KIR2DL2/3 and KIR3DL1) with HLA class I of the patients have been 
well-documented that were relevant to therapeutic effect of NK immunotherapy 
in AML [7, 66, 73]. For activating KIRs, only KIR2DS1 has been reported to associ-
ate with NK cell alloreactivities against target cells expressing HLA-C2 [60, 74]. 
Moreover, KIR haplotypes and clinical outcomes have been observed, showing 
donors with group B KIR haplotype have improved relapse—free survival for 
AML patients under unrelated HSCT [75]. With these reasons, KIR-mediated NK 
cell functions in haplo-HSCT should be taken in to account for donor selections, 
since the potential benefit of NK alloreactivity has improved survival and clinical 
outcomes in AML patients. Moreover, phase I and II clinical trials have been being 
studied to evaluate the feasibility and safety [76, 77] for further applications. 
Therefore, haplo-HSCT with T cell depletion, KIR-mediated NK cell alloreactivi-
ties should be considered for donor selections using an algorithm in which KIR-
ligand mismatches could be predicted. This is available as an online calculator 
(https://www.ebi.ac.uk/ipd/kir/ligand.html).
5.2 Acute lymphoblastic leukemia (ALL)
Since the role of alloreactive NK cells in AML were reported, the influence of 
KIR on the outcome of ALL patients in haplo-HSCT setting has been investigated. 
Like AML, the approach based upon KIR-ligand mismatches and the presence 
of donor’s KIR2DS1+ NK cells with HLA-C2 expressing target cells mediated NK 
cell alloreactivities against leukemic blasts has been tested [7]. In addition, ALL 
children transplanted from a KIR haplotype B donor showed significantly reduced 
risk of relapse, particularly in donors with high B content score [78]. However, the 
beneficial effect of NK cell alloreactivity has not been obviously noticeable in ALL 
patients in particular mechanisms of NK cells against ALL tumor cells [63, 79, 80]. 
The clinical studies of beneficial effect of NK cell alloreactivities in acute leukemia 
are summarized in Table 3.
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and effectiveness of alloreactive NK cells therapy [65]. Moreover, successfully 
transferred NK cells immunotherapy were reported in elderly AML who were 
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found to be relevant for better clinical outcomes [69, 70]. To explain the potential 
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tory signal delivered by KIR on donor’s NK cells, it has been shown that KIR2DL1+ 
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required to achieve therapeutic effect that remains inconclusive due to lack of 
standardized technical procedure for qualifying alloreactive NK cells [67, 68].  
Additionally, it became clear that infused NK cells favor IL-2 and IL-15 for expan-
sion and survival [51, 72], however, administration of IL-15 after infusion has 
been recommended because IL-2 can promote host regulatory T cells to inhibit 
allogeneic NK cells.
Given the crucial role of alloreactive NK cells in graft versus leukemia (GVL) 
effect in haplo-HSCT, the predictive algorithm for donor selection is being devel-
oped in AML treatment. Several research groups have explored feasibility of NK 
cell-based immunotherapy, including in vivo and in vitro studies as well as clinical 
trials. Predominantly, mismatches of donors’ inhibitory KIR expressing NK cells 
(2DL1, KIR2DL2/3 and KIR3DL1) with HLA class I of the patients have been 
well-documented that were relevant to therapeutic effect of NK immunotherapy 
in AML [7, 66, 73]. For activating KIRs, only KIR2DS1 has been reported to associ-
ate with NK cell alloreactivities against target cells expressing HLA-C2 [60, 74]. 
Moreover, KIR haplotypes and clinical outcomes have been observed, showing 
donors with group B KIR haplotype have improved relapse—free survival for 
AML patients under unrelated HSCT [75]. With these reasons, KIR-mediated NK 
cell functions in haplo-HSCT should be taken in to account for donor selections, 
since the potential benefit of NK alloreactivity has improved survival and clinical 
outcomes in AML patients. Moreover, phase I and II clinical trials have been being 
studied to evaluate the feasibility and safety [76, 77] for further applications. 
Therefore, haplo-HSCT with T cell depletion, KIR-mediated NK cell alloreactivi-
ties should be considered for donor selections using an algorithm in which KIR-
ligand mismatches could be predicted. This is available as an online calculator 
(https://www.ebi.ac.uk/ipd/kir/ligand.html).
5.2 Acute lymphoblastic leukemia (ALL)
Since the role of alloreactive NK cells in AML were reported, the influence of 
KIR on the outcome of ALL patients in haplo-HSCT setting has been investigated. 
Like AML, the approach based upon KIR-ligand mismatches and the presence 
of donor’s KIR2DS1+ NK cells with HLA-C2 expressing target cells mediated NK 
cell alloreactivities against leukemic blasts has been tested [7]. In addition, ALL 
children transplanted from a KIR haplotype B donor showed significantly reduced 
risk of relapse, particularly in donors with high B content score [78]. However, the 
beneficial effect of NK cell alloreactivity has not been obviously noticeable in ALL 
patients in particular mechanisms of NK cells against ALL tumor cells [63, 79, 80]. 
The clinical studies of beneficial effect of NK cell alloreactivities in acute leukemia 
are summarized in Table 3.
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6. Conclusion
This chapter sheds light on adoptive transfer NK cell immunotherapy in haplo-
HSCT setting after immunosuppressive chemotherapy. KIR-ligand mismatches, 
activating KIR with cognate ligand as well as KIR B haplotype, could contribute 
to the potential benefit of allogeneic NK cells against acute leukemia in improv-
ing relapse-free and survival in AML patients. Additionally, the donor selection 
algorithm based on KIR-ligand mismatches is provided and available. Conflicts 
resulted from studies could be explained by the different definitions of KIR ligand 
mismatches, failure of infused NK cells to expand and persist, extensive genetic 
polymorphisms as well as the stochastic surface expressions of specific KIRs on 
individual NK cells. However, some limitations still need to be elucidated in further 
studies to overcome obstacles and achieve successful NK cell immunotherapy 
and clinical impact. For example, the ligands for KIR2DL5 and KIR2DS3 are still 
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unknown. In addition, the molecular mechanisms of KIR and NK cells need to be 
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6. Conclusion
This chapter sheds light on adoptive transfer NK cell immunotherapy in haplo-
HSCT setting after immunosuppressive chemotherapy. KIR-ligand mismatches, 
activating KIR with cognate ligand as well as KIR B haplotype, could contribute 
to the potential benefit of allogeneic NK cells against acute leukemia in improv-
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polymorphisms as well as the stochastic surface expressions of specific KIRs on 
individual NK cells. However, some limitations still need to be elucidated in further 
studies to overcome obstacles and achieve successful NK cell immunotherapy 
and clinical impact. For example, the ligands for KIR2DL5 and KIR2DS3 are still 
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Based on nineteenth-century findings that showed that heat (fever) could be 
used to treat cancer, local hyperthermia has been developed as a tool to eradicate 
local tumors when surgical excision is deemed impossible. Nonetheless many 
cancer patients with advanced disease still lack effective treatment. During the 
last decades, data has emerged indicating that in situ destruction of tumors in 
some cases may induce tumor antigen release which can stimulate antigen-specific 
cellular immunity. Immune stimulating interstitial laser thermotherapy (imILT) 
is a method for local hyperthermia using laser light to increase tissue temperature 
with a specific protocol which can result in in situ vaccination. In vivo studies have 
shown that the method can induce an immune response that is effective against re-
challenging, therefore indicating abscopal effect. Data was collected during clinical 
studies to assess the safety and feasibility of the method.
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1. Introduction
The use of both light and heat in medicine has roots that reside long back in his-
tory. In ancient times, sunlight was used to treat different kinds of skin and mental 
diseases. These treatments mimic, amplify, and in some cases focus on natural 
occurring phenomena to achieve a therapeutic goal.
During the nineteenth century, it was observed that prolonged heating, as fever 
or locally externally induced hyperthermia, could cause cancerous formations to 
disappear [1–4]. Since then, many methods to treat cancer with heat were intro-
duced, from whole body to local methods such as microwave ablation, radiofre-
quency ablation, and laser ablation. The main goals with innovative treatments that 
utilize heat are to give an alternative to patients that are not suitable for surgery and 
minimize the impact of the intervention on the patient. In addition, many of these 
methods have a lower economical impact on the treating institution budget, which 
enables clinics to offer treatment to a larger number of patients.
Other methods that do not make use of heat as treating source were also devel-
oped, such as cryogenic ablation that uses subfreezing temperatures to kill the 
tumor cells or photodynamic therapy (PDT) that uses a selective combination of 
light and photoactivatable drugs to induce radicals in the tumor.
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minimize the impact of the intervention on the patient. In addition, many of these 
methods have a lower economical impact on the treating institution budget, which 
enables clinics to offer treatment to a larger number of patients.
Other methods that do not make use of heat as treating source were also devel-
oped, such as cryogenic ablation that uses subfreezing temperatures to kill the 
tumor cells or photodynamic therapy (PDT) that uses a selective combination of 
light and photoactivatable drugs to induce radicals in the tumor.
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Interest in focal ablation of tumors increased significantly in the last decades 
because of indications that local treatment may cause shrinkage of untreated, in 
some cases distant, tumors suggesting the involvement of the immune system in the 
process [5–7]. The so-called abscopal effect evoked by local treatments could be used 
to treat patients that lack effective treatments to date. Immune stimulating interstitial 
laser thermotherapy is an innovative hyperthermia treatment that uses a specifically 
tailored treatment protocol based on lower temperature heating for a prolonged 
period of time and designed to maximize the probability of triggering the immune 
system response to the treated tumor type. The medical device system uses laser as 
heat source; the same system is also used for interstitial laser ablation to burn tumor-
ous and non-tumorous formation when imaging is challenging given its natural MR 
compatibility.
2. Laser-induced hyperthermia
Laser-based hyperthermia, known as laser thermotherapy or laser ablation, is a 
focal hyperthermia technique that uses laser light as heat source. Its minimally inva-
sive version for treatment of tumors located deeper in the body is called interstitial 
laser thermotherapy (LITT or ILT). The main goal in oncological treatments is to 
achieve tumor destruction without damaging tissue and structures surrounding the 
neoplastic lesion to be treated. Different factors concur to the tissue destruction, 
among these direct cell death and coagulation.
During laser-induced thermotherapy, light causes damage in tissue due to 
absorption of light and through heat conduction into the tissue of the absorbed 
energy. Laser thermotherapy therefore produces a lesion that is larger than the 
volume where light is absorbed due to this heat conduction.
These two phenomena, direct light absorption and heat conduction, determine 
the modality and the parameters to be used to control the tumor heating and are 
dependent on the characteristics of the tissue to be treated.
2.1 Direct tissue absorption
The penetration depth, which is defined as the distance at which the light is 
attenuated to 1/e (37% of original intensity), can be used to describe the volume 
in which the main part of the laser energy is absorbed in tissue, i.e., where direct 
absorption is the dominant factor. Penetration depth can also be used to deter-
mine whether the possibility for carbonization during ablation is affected by, for 
example, the choice of the wavelength. Low penetration depth indicates a higher 
power density in tissue and thereby a higher risk of carbonization. Therefore 
it is an important factor to be taken into consideration both when designing 
the optical fibers to deliver the light and when deciding on suitable treatment 
parameters.
Penetration depth depends on the tissue type since the optical properties are 
dependent on tissue composition and structure. For a generic tissue composition, 
the effective attenuation coefficient and the penetration depth can be calculated as 
follows:
  μ eff =  √ 
_______________
  3  μ a ( μ a +  μ s (1 − g) ) (1)
  δ eff =  1 ⁄ μ eff  (2)
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Values for μa, μs, and g, in different tissue types, are available in textbooks deal-
ing with optical properties in tissue, e.g., [8].
The absorption, μa, of a specific tissue depends on the tissue composition. Each 
component has a specific absorption spectrum. Biological tissue has a relatively low 
absorption in the interval 600–1200 nm. This is due to the fact that the absorption 
spectrum of the main component of tissues, water, has a minimum in this region. 
Other tissue components, especially blood, must also be considered. In Figure 1, 
only the major absorbers for the specific wavelength in use are shown.
The scattering, μs, depends on the tissue structure, for example, on the cell size 
and shape, and how they are arranged in the tissue. Light scattering in tissue has 
two contributions, Rayleigh and Mie scattering; the latter is usually predominant 
due to the scattering of particle size. The scattering is inversely proportional to the 
wavelength: as the wavelength increases, the scattering coefficient diminishes. As 
the two wavelengths considered are spectrally close, the scattering coefficients are 
similar. The scattering spectrum for a generic soft tissue is shown in Figure 2 and 
was calculated according to [9]:
  (3)
The equation takes into consideration different scattering contributions mainly 
due to the different sizes of the scattering centers.
All the parameters are tissue dependent. The values for a generic soft tissue in 
Table 1 were used in Figure 2.
2.2 Heat conduction in biological tissue
The energy deposited in tissue causes an increase in temperature in the portion 
of tissue where laser light is absorbed. Naturally, the difference in heat evens out 
over time. The heat is removed from the volume where absorption of light occurs by 
active or passive cooling. Active cooling is achieved through blood perfusion, which 
varies during time according to response of the tissue to heat and is dependent on 
the perfusion rate and therefore on the tissue type. Passive cooling is due to heat 
Figure 1. 
Absorption spectra of tissue components in the window 500–1100 nm. Dotted line at 1064 nm.
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conduction and is described by the second law of thermodynamics which asserts 
that heat flows spontaneously from hot to cold bodies, in this case from the heated 
portion of tissue to the portion of tissue at body temperature.
If the delivered energy is high enough, the heat conduction concurs to the 
progression of the damage since heat conduction can cause tissue temperatures to 
rise well above the threshold for permanent damage. The threshold for permanent 
tissue damage is discussed in the following paragraphs.
Pennes’ equation models heat distribution in the tissue:
  (4)
The equation describes the heat flow in the tissue as the combination of 
(passive) heat conduction, (active) heat transport due to blood perfusion and 
dependent on the temperature difference, metabolic heat source which is the heat 
produced by the tissue itself, and the external heat source, in this case the laser 
energy [10–12].
2.3 Laser-induced tissue effects
Effects on biological tissues induced by lasers can vary in nature and can be 
classified in several groups among which are photochemical damage, when light 
triggers a chemical reaction in the tissue, and thermal effects, when heat is the 
cause of the outcome. Photochemical damage includes radical formation and tissue 
inflammation, while examples of thermal damage are protein denaturation and 
burning. The type of damage triggered depends mainly on the characteristics of the 
Figure 2. 







Scattering parameters for a generic tissue [9].
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light beam (wavelength, power, pulse properties, exposure time, spot size) and if 
the beam is collimated, i.e., laser source.
Thermal effects are caused when the temperature in the tissue is locally 
increased over the physiological temperature; the threshold is generally set to 
40°C. Conditional to the specific tissue properties, beam characteristics and expo-
sure times, the tissue can undergo hyperthermia (<60°C), coagulation, vaporiza-
tion, carbonization, or pyrolysis. Hyperthermia can be reversible or irreversible 
depending on the combination of temperature reached and exposure time. Local 
ablation techniques, such as microwave, radiofrequency, or laser ablation, aim at 
achieving a temperature of at least 60°C in the whole treated volume, therefore 
inducing cell death by coagulation; vaporization and carbonization may occur.
3.  Laser ablation and immune stimulating interstitial laser 
thermotherapy (imILT)
Classic laser ablation is used to treat solid tumor masses in a variety of organs 
and aims at heating the whole tumor volume at a temperature of at least 60°C in 
order to coagulate the tissue in the area to be treated. In this way, near to instant cell 
death is achieved. An optical fiber is placed in the center of the region of inter-
est, and light is delivered for a period of time of 1–10 minutes depending on the 
volume to ablate and the device used. The treatment can be repeated directly after 
to achieve larger coagulation volume either inserting the fiber in a new position or 
utilizing the so-called pull-back technique, meaning performing a new ablation 
along the insertion track by pulling the fiber back.
Immune stimulating interstitial laser thermotherapy (imILT) is a local abla-
tion method that works at non-coagulating temperatures at the tumor border. The 
technique consists in creating a temperature gradient in the tumor that results in a 
heating to 46°C at the tumor border or some millimeters outside it. The tempera-
ture is then kept for a prolonged period of approximately 30 minutes to achieve an 
immunogenic cell death (ICD) at the tumor border, visible only 48–72 hours after 
treatment, which activates an immune response [13, 14]. An example of ablation 
achieved performing an imILT treatment is shown in Figure 3. The biological 
process is not fully understood to date, but the hypothesis is that imILT creates 
inflammation in the tumor. Damage-associated molecular pattern (DAMP) signal 
is created, and antigens, which are not coagulated due to the low temperatures, are 
released [7, 15–17]. The antigens are picked up by antigen-presenting cells (APCs) 
that in turn trigger an immune response [18–21].
The method can in principle be used to treat all types of solid tumors, but some 
types will be more responsive than others depending on the tumor biology, which is 
true for immunotherapies in general. Some results from proof-of-concept preclini-
cal and clinical studies are presented in this chapter.
3.1 Technical solutions for interstitial laser thermotherapy
The CE-marked and FDA-approved TRANBERG® Thermal Therapy System for 
imILT consists of three main parts: a laser generator, a laser applicator, and a ther-
mometry system. The laser generator is a diode-based system that emits light at a 
wavelength of 1064 nm and with a maximum accessible power of 25 W continuous 
wave. The unit has a built-in temperature feedback system that is able to measure 
the temperature in the tissue by means of a minimally invasive temperature probe 
and to drive the laser emission in order to maintain a stable temperature, set by 
the user between 43 and 50°C, for a treatment time of up to 30 minutes. The laser 
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applicator consists of a non-cooled optical fiber and an introducer to enable inser-
tion of the fiber in the tissue. The non-cooled optical fiber is available in different 
tip designs tailored to the ablation volume and shape to be achieved and the tissue to 
be treated.
All the procedures are performed under image guidance, using MRI, ultrasound, 
computed tomography (CT), or a combination of the previous depending on the 
availability of these techniques at the clinic. While it is only possible to perform 
imILT treatments using ultrasound or CT guidance due to limitations in the temper-
ature probe design, the design of the laser applicator allows laser ablation procedure 
to be performed with MRI guidance, for example, when performing a focused 
laser ablation (FLA) for the treatment of early prostate cancer or benign prostatic 
hyperplasia (BPH).
3.2 In vivo studies on abscopal effect of imILT
Extensive preclinical studies were performed to prove the immune stimulating 
effects of imILT. One specific study aimed at comparing the immunologic memory 
evoked by imILT if compared to resection [22].
Research was conducted on 280 rats divided in four groups: (1) rats with tumor 
implanted in the liver that were treated with imILT, (2) rats with tumors implanted 
in the liver that were treated with surgical resection, (3) rats without tumor that 
were treated with imILT ablating normal liver tissue (sham imILT), and (4) rats 
without tumors that were treated with resection of a part of a healthy liver (sham 
resection).
Figure 3. 
Effect of imILT treatment on porcine healthy skeletal muscle tissue. Coagulation is achieved within the yellow 
circle, and immunogenic cell death (ICD) is achieved along the ablation border, between the yellow and the 
blue line.
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Rats in groups 1 and 2 were implanted with adenocarcinoma and treated after 
6–8 days. A second challenging tumor of the same kind was implanted in another 
lobe 2, 5, or 10 weeks later, and the animals were followed for up to 48 days after 
rechallenge unless they showed signs of inactivity or distress earlier. Vital tumor at 
sacrifice was evaluated together with other immune system markers. Group 1, tumor 
treated with imILT, showed a distinct behavior if compared with the other three 
groups. In groups 2, 3, and 4, the challenging tumor, second implanted, displayed a 
growth so substantial that none of the rats survived for 48 days. On the contrary, rats 
in group 1 showed eradication of the challenging tumor at day 48. The extent of the 
tumor burden for the four groups is represented in Figure 4. These findings, com-
bined with results from immunology markers from blood tests, indicate that imILT 
invokes a strong immune response and an immunologic memory against the treated 
cancer.
3.3 Clinical results
A number of pre-marketing clinical studies on imILT were performed at Lund 
University Hospital, Lund, Sweden, where the method was developed for the first 
time. These studies demonstrated the recruitment of immunocompetent cells in 
breast cancer patients which indicate a favorable antitumor activity [23–27].
More recently, initial findings from the clinical study program designed 
to evaluate the safety and the usability of the method performed using the 
TRANBERG®|Thermal Therapy System (Clinical Laserthermia Systems, AB, 
Sweden) were published [28]. A variety of solid tumors are included in the study 
program; the data was reported after 12 patients were treated, out of which 4 were 
female and 8 were male. Indications treated were breast cancer (n = 1), breast 
cancer metastasis (n = 1), colon cancer metastasis (n = 2), malignant melanoma 
metastasis (n = 2), pancreatic carcinoma (n = 1), and primary pancreatic carcinoma 
(n = 5); the latter two were treated in open surgery, while the other percutaneously. 
All the treatments were performed using CT or ultrasound guidance. All patients 
included in the study underwent numerous previous treatments due to comorbidity. 
Figure 4. 
Tumor burden after implantation of challenging tumor. Only rats having been treated with imILT of primary 
tumor survived for 48 days after implantation of challenging tumor. All other rats in the 48-day study group 
had to be euthanized within 10–30 days after the tumor challenge due to extensive tumor. Image: Mats Ekelund.
Cancer Immunotherapy and Biological Cancer Treatments
76
applicator consists of a non-cooled optical fiber and an introducer to enable inser-
tion of the fiber in the tissue. The non-cooled optical fiber is available in different 
tip designs tailored to the ablation volume and shape to be achieved and the tissue to 
be treated.
All the procedures are performed under image guidance, using MRI, ultrasound, 
computed tomography (CT), or a combination of the previous depending on the 
availability of these techniques at the clinic. While it is only possible to perform 
imILT treatments using ultrasound or CT guidance due to limitations in the temper-
ature probe design, the design of the laser applicator allows laser ablation procedure 
to be performed with MRI guidance, for example, when performing a focused 
laser ablation (FLA) for the treatment of early prostate cancer or benign prostatic 
hyperplasia (BPH).
3.2 In vivo studies on abscopal effect of imILT
Extensive preclinical studies were performed to prove the immune stimulating 
effects of imILT. One specific study aimed at comparing the immunologic memory 
evoked by imILT if compared to resection [22].
Research was conducted on 280 rats divided in four groups: (1) rats with tumor 
implanted in the liver that were treated with imILT, (2) rats with tumors implanted 
in the liver that were treated with surgical resection, (3) rats without tumor that 
were treated with imILT ablating normal liver tissue (sham imILT), and (4) rats 
without tumors that were treated with resection of a part of a healthy liver (sham 
resection).
Figure 3. 
Effect of imILT treatment on porcine healthy skeletal muscle tissue. Coagulation is achieved within the yellow 
circle, and immunogenic cell death (ICD) is achieved along the ablation border, between the yellow and the 
blue line.
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Rats in groups 1 and 2 were implanted with adenocarcinoma and treated after 
6–8 days. A second challenging tumor of the same kind was implanted in another 
lobe 2, 5, or 10 weeks later, and the animals were followed for up to 48 days after 
rechallenge unless they showed signs of inactivity or distress earlier. Vital tumor at 
sacrifice was evaluated together with other immune system markers. Group 1, tumor 
treated with imILT, showed a distinct behavior if compared with the other three 
groups. In groups 2, 3, and 4, the challenging tumor, second implanted, displayed a 
growth so substantial that none of the rats survived for 48 days. On the contrary, rats 
in group 1 showed eradication of the challenging tumor at day 48. The extent of the 
tumor burden for the four groups is represented in Figure 4. These findings, com-
bined with results from immunology markers from blood tests, indicate that imILT 
invokes a strong immune response and an immunologic memory against the treated 
cancer.
3.3 Clinical results
A number of pre-marketing clinical studies on imILT were performed at Lund 
University Hospital, Lund, Sweden, where the method was developed for the first 
time. These studies demonstrated the recruitment of immunocompetent cells in 
breast cancer patients which indicate a favorable antitumor activity [23–27].
More recently, initial findings from the clinical study program designed 
to evaluate the safety and the usability of the method performed using the 
TRANBERG®|Thermal Therapy System (Clinical Laserthermia Systems, AB, 
Sweden) were published [28]. A variety of solid tumors are included in the study 
program; the data was reported after 12 patients were treated, out of which 4 were 
female and 8 were male. Indications treated were breast cancer (n = 1), breast 
cancer metastasis (n = 1), colon cancer metastasis (n = 2), malignant melanoma 
metastasis (n = 2), pancreatic carcinoma (n = 1), and primary pancreatic carcinoma 
(n = 5); the latter two were treated in open surgery, while the other percutaneously. 
All the treatments were performed using CT or ultrasound guidance. All patients 
included in the study underwent numerous previous treatments due to comorbidity. 
Figure 4. 
Tumor burden after implantation of challenging tumor. Only rats having been treated with imILT of primary 
tumor survived for 48 days after implantation of challenging tumor. All other rats in the 48-day study group 
had to be euthanized within 10–30 days after the tumor challenge due to extensive tumor. Image: Mats Ekelund.
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Immunotherapy was delivered on two malignant melanoma patients before imILT 
treatment but not during the study period.
One serious adverse event was reported out of nine patients within the spon-
sor initiated clinical study; the frequency of serious adverse events is in line with 
previous data on other local ablative techniques, including laser ablation [29, 30], 
indicating that the procedure can be safely performed.
Usability results vary among the different study clinics. Preliminary indications 
suggest that insertion and placement of the instrumentation within the volume to 
be treated are the main challenge, while sterile access, removal from the tissue, and 
handling of disposable are perceived as less complicated. Handling of the laser unit 
needs further investigation as the data is spread [28].
The safety studies were not designed to collect statistically significant efficacy 
results. Each study included different indications to gather safety data and input to 
future efficacy studies as extensive as possible leading to a low number of patients 
per indication, and therefore no indication-based data was published. Future 
ongoing publications will include indicative efficacy and quality-of-life results from 
these studies.
3.3.1 Case report
This case is a 53-year-old patient with pancreatic cancer diagnosed about 2 years 
before and treated with first-line chemotherapy, FOLFIRINOX 16 cycles, for tumor 
reduction. Disease progression was registered after 12 cycles. Due to intolerable toxic-
ity, the treatment regimen was changed to second- and third-line chemotherapies, 
gemcitabine and protein-bound paclitaxel 16 cycles, after which partial response 
was achieved. At the time of the first imILT treatment 2 years after the diagnosis, the 
patient presented with pancreatic carcinoma and three liver metastases (stage IV). 
PET-CT showed a hypermetabolic focus around the biliary stent, but no clearly visible 
tumor in the pancreas, and three metastases in the liver (segments VI, V/VI, and V/
peri-gallbladder area).
The first treatment was performed on a 19 mm liver metastasis in segment VI 
that was metabolically active; see Figure 5. The intervention was performed percu-
taneously under CT guidance, and a first treatment was performed by placing the 
tip of the radial laser applicator in the metastasis—see Figure 6—and a temperature 
Figure 5. 
PET-CT (left) and CT (right) scans showing the position of the treated metastasis during the first treatment 
session [31].
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needle at a distance of approximately 10 mm. The temperature needle was used to 
regulate the laser emission based on the measured temperature and achieve ICD in 
a region of the lesion that presented as metabolically active from the PET scan. A 
temperature of 44–45°C was kept during a period of 30 minutes according to the 
imILT protocol. A second overlapping ablation was performed after repositioning 
the laser applicator to necrotize the whole volume of the metastasis. Track ablation 
was performed to minimize risk for track seeding of tumor cells along the inser-
tion track. A post-procedure CT scan was performed to ensure the ablation of the 
entire tumor, which was achieved as shown in Figure 7 (black arrow). The patient 
suffered slight pain and rise in temperature (38°C) posttreatment, but no other 
Figure 6. 
Laser applicator positioning visualized using CT scan while placing the instrumentation for the first 
treatment [31].
Figure 7. 
Posttreatment CT that shows the ablation cavity (black arrow) and the biliary stent (white arrow). First 
treatment session [31].
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discomfort was registered; the patient was discharged after 3 days. No complica-
tions were reported during the first 3 months following therapy [31].
Partial response in liver metastasis and total response in pancreas primary tumor 
were registered 21 months later. However, 3 months later disease progression was 
noticed, and the patient was treated with imILT for a second time 24 months after 
the initial treatment. The targeted metastasis was a 35 × 50 mm liver metastasis 
evaluated at ultrasound at the time of the treatment. The metastasis was treated 
performing one imILT treatment combined with an overlapping LITT treatment of 
about 5 minutes to necrotize the whole metastatic mass; the imILT treatment was 
achieved positioning the radial laser applicator off center within the tumor and the 
temperature probe at a distance of approximately 11 mm from the applicator. The 
temperature measured by the probe was kept at 43–45°C for 20 minutes.
Lastly, a third imILT treatment was performed after 40 months from the first 
treatment because of new disease progression. A new 20 mm liver metastasis was 
treated using a diffuser laser applicator combined with an introducer with built-in 
temperature sensors, which resulted in only one puncture. The laser applica-
tor was inserted in the center of the metastasis, and the sensors were positioned 
25 mm from the applicator tip to achieve a lesion of 25–30 mm in diameter. To date, 
4 months after the last treatment, no complications connected to the laser treat-
ment have been reported [32].
4. Conclusion
Local ablation of tumors is receiving increasing attention for the treatment of 
metastatic disease because of observed effects on distant tumorous masses suggest-
ing the involvement of the immune system following local therapy.
One technique for local tumor eradication is laser ablation which kills the tumor 
mass by heating the tissue through direct light absorption and heat transfer result-
ing in tissue coagulation. imILT is an interstitial laser ablation method tailored 
to evoke an immune response against the treated tumor. The technique utilizes a 
laser applicator to deliver energy in the form of laser light to the tissue; the energy 
delivered to the tissue is precisely controlled based on the temperature measured 
by a sensor inserted in the tissue at the periphery of the tumor to obtain a lower 
temperature ablation that aims at maximizing the immune cell death (ICD) volume 
of the ablation.
Preclinical results indicate that imILT invokes an immune response against the 
treated tumor, if compared with resection in a rat tumor model. Clinical studies 
suggest that the procedure can be safely performed since the frequency of the 
adverse events is in line with previous data on other local ablation techniques. The 
case of a pancreatic cancer patient treated with imILT was presented.
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Abstract
Benign spinal cord tumors (SCTs) are uncommon neoplasms that can arise 
within or adjacent to the spinal cord. Depending on their anatomical location, 
benign SCTs can be categorized as intramedullary, intradural-extramedullary, and 
extradural. The three most common benign SCTs are meningioma, nerve sheath 
tumors, and ependymoma. Both meningioma and nerve sheath tumors develop 
in the intradural-extramedullary compartment, while ependymoma occurs in the 
intramedullary space. Spinal meningiomas derive from arachnoidal cells and most 
commonly occur within the thoracic segment of the spine. Nerve sheath tumors, 
including schwannomas and neurofibromas, are closely associated with spinal 
nerves. Half of the spinal cord ependymomas arise in the lumbosacral segment or 
the filum terminale. Surgical treatment of large or symptomatic benign SCTs con-
centrates on total or subtotal resection of the tumors, which should be cautiously 
individualized based on the tumor location and histopathology. A curable com-
plete resection should be achieved if possible while preserving the nervous func-
tion of the spinal cord and minimizing potential complications. Thoracic spinal 
roots may be sacrificed to acquire a total resection, yet cervical and lumbar nerve 
roots should be preserved prudently. Due to the vulnerable and complex anatomic 
nature of the spinal cord, maximal resection of the tumors can be achieved with 
the aid of appropriate intraoperative neural monitoring and meanwhile preserve 
nervous function.
Keywords: benign spinal cord tumors, surgical treatment, pathology of benign spinal 
cord tumors, CSF leakage
1. Benign spinal cord tumors
Spinal cord tumors are abnormal mass of tissue that could occur within or 
adjacent to the spinal cord. They can be benign or malignant. Benign spinal cord 
tumors are usually rare primary tumors originating in the spinal or spinal cord. 
Based on their location, they can be categorized as intramedullary, intradural-
extramedullary, and extradural (Figure 1).
Intramedullary tumors arise inside the spinal cord itself, typically derived from 
glial or ependymal cells. Astrocytoma and ependymoma are the two most common 
types, and they usually occur in the cervical segments. Intradural-extramedullary 
spinal cord tumors arise within the dura but outside of the spinal cord. The most 
common types are meningiomas, nerve sheath tumors including schwannomas and 
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tumors are usually rare primary tumors originating in the spinal or spinal cord. 
Based on their location, they can be categorized as intramedullary, intradural-
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Intramedullary tumors arise inside the spinal cord itself, typically derived from 
glial or ependymal cells. Astrocytoma and ependymoma are the two most common 
types, and they usually occur in the cervical segments. Intradural-extramedullary 
spinal cord tumors arise within the dura but outside of the spinal cord. The most 
common types are meningiomas, nerve sheath tumors including schwannomas and 
Cancer Immunotherapy and Biological Cancer Treatments
86
neurofibromas, and myxopapillary ependymomas that occur on the filum termina-
lis and the conus medullaris. Extradural spinal cord tumors are mostly metastatic 
and malignant, which is not covered here.
2. Symptoms
Early symptoms of spinal cord neoplasms are often nonspecific. Gradually 
worsening back pain is the initial feature of spinal cord neoplastic disease in about 
90% of adult patients. Spinal cord compression can have a subtle presentation. Pain 
often precedes other symptoms associated with spinal cord compression and causes 
nocturnal awakening. Discomfort may be radicular, localized to the back, or both. 
Patients often describe this pain as a gnawing and unremitting. Radicular pain sug-
gests nerve root impingement and may provide an indication of the location of the 
tumor. Neurologic dysfunction distal to the lesion is due to interruption of ascend-
ing and descending spinal cord pathways. The most common sequelae are sensory 
dysesthesias and muscular weakness, especially of the iliopsoas musculature. Once 
symptoms other than pain appear, they may progress rapidly. Tumors intrinsic 
or extrinsic to the spinal cord can cause symptoms through disruption of normal 
neural elements and pathways, producing both local and distal effects. Sensory 
or motor symptoms that may be referred to the cord include limb paresthesia and 
weakness. Paraplegia and bowel or bladder disturbances (e.g., constipation, urinary 
hesitancy, retention, incontinence) are usually late findings except in conus medul-
laris syndrome, in which sphincter dysfunction and saddle anesthesia may emerge 
early in the course. Although neurologic manifestations may begin unilaterally, they 
can progress to involve both sides of the spinal cord and thereby produce bilateral 
symptoms and signs.
Figure 1. 
Illustration of spinal cord tumor locations: intramedullary, intradural-extramedullary, and extradural.
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3. Physical examination
Findings on physical examination could define a probable site of tumor, docu-
ment preoperative neurologic deficits, and determine progressive neurologic 
deterioration. They usually correspond to the location of the tumor, degree of 
cord impingement, and duration. Early in the course of spinal cord compression, 
spasticity, hyperreflexia, and loss of pinprick, temperature, position, and vibra-
tory sensation may occur, while the Babinski may be absent. Tenderness over the 
affected spinal region can present. Late in the course of spinal cord compression, 
weakness, clear sensory loss, bilateral Babinski signs, and decreased anal sphincter 
tone, hyperreflexia and Babinski can be present. Lax rectal sphincter tone is a late 
sign of spinal cord dysfunction. Lhermitte’s sign suggests irritation of the menin-
geal irritation. Brown-Sequard syndrome is caused by lateral spinal cord compres-
sion. Cauda equina syndrome and conus medullaris syndrome can be present as a 
result of compression of the spinal cord and nerve roots arising from L1–L5 levels.
4. Pathology
4.1 Intramedullary tumors
The majority of intramedullary primary spinal cord tumors are gliomas. Due 
to the relative paucity of glial tissue in the spinal cord, spinal cord gliomas are rare 
compared to their cerebral counterparts. The major types of spinal glial tumors are 
ependymomas and astrocytomas.
4.2 Ependymomas
Ependymomas are intramedullary tumors that may be located anywhere 
along the spinal cord. Over 50% occurs in the filum terminale; the other 50% can 
occur anywhere in the cervical or thoracic spinal cord [1]. In the World Health 
Organization (WHO) classification of brain tumors, ependymal tumors are divided 
into four major groups: sub-ependymoma (WHO Grade I), myxopapillary epen-
dymoma (WHO Grade I), ependymoma (WHO Grade II), and anaplastic ependy-
moma (WHO Grade III).
4.3 Ependymoma
Ependymomas are more common in adults, with a peak age at presentation 
between 30 and 40 years. Histologically, they can be categorized to papillary, cel-
lular, epithelial, or mixed. The cellular subtype is most common. Clinically, patients 
often have localized pain for months to years prior to developing other symptoms 
leading to diagnosis. Physical exam findings include lower extremity spastic-
ity, loss of pain and temperature sensation, lower extremity and truncal sensory 
diminution to light touch and vibration, as well as gait ataxia. Ependymomas tend 
to arise centrally within the cord and expand symmetrically as they grow. Cystic 
degeneration occurs in about 46% of the cases [2, 3]. They are usually encapsulated 
and minimally vascular. These lesions generally enhance intensely on MRI. Optimal 
management consists of gross total resection. Although these are infiltrative 
tumors, a total or near-total resection can frequently be achieved without causing 
further neurologic deficits.
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tumors, a total or near-total resection can frequently be achieved without causing 
further neurologic deficits.
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4.4 Myxopapillary ependymoma
Myxopapillary ependymomas are biologically and morphologically distinct from 
other ependymomas (Figures 2 and 3). These tumors most commonly arise in the 
conus medullaris and the filum terminale. At this anatomic location, ganglioglioma 
and lipoma are the second and third most commonly seen tumors separately follow-
ing myxopapillary ependymoma. Myxopapillary ependymomas are WHO Grade I 
and usually solitary. They are papillary with microcystic vacuoles. Myxopapillary 
ependymomas are slow-growing glial tumors, sometimes with an indolent course 
for long periods of time. They typically are found in young male, with a median age 
at diagnosis from 35 to 37 years, and a male to female ratio ranging from 1.4 to 2.5 to 
1 [4, 5]. Myxopapillary ependymomas generally present with low back pain, with 
or without radicular features. The vast majority of these tumors are located in the 
lumbosacral or thoracolumbar spine. Initial management of these tumors consists 
of laminectomy with attempted surgical resection. These tumors oftentimes can 
be totally resected, and many patients are cured following gross total resection. 
Subtotal resection deems necessary in particular with unencapsulated tumors. As 
postoperative radiotherapy tends to improve local control and prolong the recur-
rence-free interval, it may be considered in patients who have undergone subtotal 
resection or biopsy of a myxopapillary ependymoma. However, radiotherapy is still 
controversial since its effect on overall survival is unclear.
4.5 Astrocytomas
Astrocytomas occur throughout the spinal cord with the thoracic segment being 
the most common site. Approximately 50% of spinal cord astrocytomas is pilocytic, 
and 50% is infiltrative astrocytomas. Pilocytic astrocytomas are well circumscribed 
and low grade with nonaggressive clinical behavior. On MRI these tumors enhance 
intensely with gadolinium. Low-grade astrocytomas are shown as hypointense to 
Figure 2. 
Encapsulated myxopapillary ependymoma: (A) T1WI shows isointense mass, (B) T2WI shows slightly 
hyperintense mass with capsule, and (C) T1 with contrast shows enhancement of the mass.
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isointense signal on T1-weighted images and hyperintense signal on T2-weighted 
images [6]. Diffuse fibrillary astrocytomas of the spinal cord usually appear as 
nonencapsulated lesions that enhance minimally or heterogeneously on MRI with 
gadolinium. Peak diagnosis ranging from the third to the fifth decade, with a 
median age 35 years. Male to female ratios are about 1.5 to 1. The most important 
factor associated with a better prognosis is low tumor grade (WHO Grade I). Other 
factors associated with a better prognosis include tumor location other than the cer-
vical region, limited extent of tumor involvement along the spinal cord, and longer 
(>180 days) duration of symptoms. Postoperative radiotherapy does not affect out-
comes in patients with pilocytic astrocytomas. The initial step in the management 
of a patient with a symptomatic or enlarging presumed primary intramedullary 
spinal cord tumor is a surgical procedure for tissue diagnosis and resection to the 
maximum extent possible. Pilocytic astrocytomas can often be completely or near-
completely resected without causing further neurologic deficits. Diffuse fibrillary 
astrocytomas are more infiltrative, and meaningful resection is often precluded by 
the lack of clear tissue planes and high risk of neurologic morbidity, in which case 
an internal debulking procedure would be performed.
5. Intradural-extramedullary tumors
Both meningiomas and nerve sheath tumors (schwannomas and neurofibromas) 
can develop in the intradural-extramedullary spinal compartment.
5.1 Meningioma
Meningiomas can arise from arachnoidal cap cells anywhere along the neuraxis. 
Spinal meningiomas most commonly arise within the thoracic spine. Over three 
Figure 3. 
Focal hyalinized vessels (left) and perivascular pseudorosettes (right) are characteristic histological features of 
WHO Grade I myxopapillary ependymoma.
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fourths occur in women. The tumors are frequently adherent to the spinal dura, 
requiring dural resection for complete removal. The tumors can be intradural, 
extradural, and a mixture of intradural and extradural. Psammomatous meningio-
mas are the most common histological subtypes of spinal meningioma (Figure 4). 
Spinal meningiomas are typically slowly growing, invasive lesions and may remodel 
or erode bone. Pathologically, spinal meningiomas demonstrate the same features 
seen with intracranial lesions. Calcifications may be suggestive of the histologic 
diagnosis of meningioma. Local or radicular pain is the most common symptom 
associated with spinal meningiomas, followed by motor deficits and sensory 
symptoms. On MRI, meningiomas are iso- to hypointense on T1 and slightly 
hyperintense on T2, with a strong and homogeneous enhancement with gado-
linium (Figure 5). The usual treatment for spinal meningiomas is resection, and 
complete resection can often be achieved. The dural origin is generally cauterized 
and occasionally resected. Thoracic spinal roots may be sacrificed as necessary to 
achieve a complete resection; cervical and lumbar nerve roots are preserved when-
ever possible. Recurrence rate with complete excision is 7% [7]. Subtotally resected 
lesions are generally followed expectantly for regrowth. Symptomatic recurrences 
are generally treated with further surgery.
5.2 Nerve sheath tumors
Nerve sheath tumors constitute about 25% of tumors arising from the dorsal 
sensory root near the edge of its exit from the spinal canal in the intradural-extra-
medullary space. Majority of nerve sheath tumors are schwannomas (Figure 6A), 
and most of the remainder are neurofibromas. Nuclear palisading (Verocay bodies) 
is a typical feature in schwannomas, with spindle cells arranged in short, intersecting 
fascicles. Neurofibromas grow as fusiform expansions of the involved nerve. They 
are less compact and less cellular than schwannomas. Spindle-shaped tumor cells 
with a wavier or buckled nuclear profile are typical to neurofibromas. Schwannomas 
and neurofibromas typically are slow growing. Patients generally present with local 
pain initially, which typically worsens at night or in the morning and resolves during 
the day. Neurologic deficits develop late in the course of the disease when they fill a 
significant volume of the spinal canal. As the tumor grows, it extends to the epidural 
space through the narrowest portion of the course of the nerve root, forming a 
“dumbbell-shaped” tumor (Figure 6B), which is rather radiographically typical. 
Small, asymptomatic tumors are best observed with serial imaging before commit-
ting to definitive surgical therapy. Large or symptomatic tumors are best treated with 
surgeries. The goal of the surgery is to achieve gross total resection of the benign 
Figure 4. 
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tumors, yet a subtotal resection should be obtained to spare neurological function 
impairment as most of the tumors are benign and slow growing.
6. Surgical treatment
6.1 Surgical anatomy
The adult spine consists of 33 individual vertebrae, which are divided into the 
cervical, thoracic, lumbar, sacral, and coccygeal vertebrae. The vertebrae are joined 
Figure 5. 
(A) T2WI, a round slightly hyperintense mass is seen in the intradural space. (B) MRI contrast image shows 
homogeneous enhancement.
Figure 6. 
(A) T1 with contrast: Schwannoma shows enhancement and (B) T2WI shows a “dumbbell-shaped” 
schwannoma.
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by cartilaginous interbody joints, synovial facet joints, spinal ligaments, and overly-
ing muscles and fasciae. The vertebral foramina constitute the vertebral canal, 
which contains the spinal cord, nerve roots, meninges, and vasculatures. Adjacent 
vertebrae form the intervertebral foramina laterally, where the spinal nerves and 
vessels go through. The posterior portion of the vertebra is called the vertebral 
arch, which consists of a pair of pedicles and a pair of laminae supporting articular 
processes, transverse processes, and the spinous process. Reconstruction of the 
vertebral arch is critical in a surgical treatment of spinal tumors via a posterior 
surgical approach (Figure 7).
The spinal cord runs within the superior two thirds of the vertebral canal from 
the medulla oblongata to the conus medullaris. The anterior median fissure extends 
along the whole ventral surface and runs deeper caudally. The posterior median 
sulcus is shallower, from which a posterior median septum penetrates more than 
halfway in to the spinal cord. The septum diminishes caudally as the canal becomes 
more dorsally placed. Lateral to each side of the posterior median sulcus lies the 
posterolateral sulcus, along which the dorsal roots of spinal nerves enter the cord. 
Between the posterolateral sulcus and anterior median fissure is the anterolateral 
funiculus, where the ventral spinal rootlets pass through.
The paired dorsal and ventral roots of the spinal nerves are continuous with the 
spinal cord. They unite in or close to their correspondent intervertebral foramina to 
form the spinal nerves. There are 31 pairs of spinal nerves branching off the spinal 
cord. The section of spinal cord associated with the emergence of a pair of nerves is 
named a spinal segment.
The conus medullaris is the tapered, lower end of the spinal cord near L1 or L2 
vertebra. The upper conus medullaris is usually not well defined. The level at which 
the spinal cord ends variates in population. The vertebra column elongates more 
rapidly than the spinal cord during development, hence the discrepancy between 
the anatomical level of spinal cord segments and their corresponding vertebrae. The 
spinal nerves continue to branch out after the conus medullaris, forming the cauda 
equina, which is gathered round the filum terminale. The pia mater surrounding 
Figure 7. 
Illustration of a cross-section anatomy of the spinal cord showing deep anterior median fissure, shallow 
posterior median sulcus, and shallow grooves of anterolateral or posterolateral sulcus.
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the spinal cord projects directly downward, forming the filum terminale. The filum 
terminale, descending from the apex of the conus medullaris, is continued within 
extensions of the dural and arachnoid meninges and reaches the caudal border of 
the second sacral vertebra, stabilizing the entire spinal cord.
The spinal cord is covered by the meninges. The outermost membrane is the 
spinal dura mater which forms a tube. The spinal cord is directly covered by the 
thin, translucent membrane of the pia mater, which itself comprises an inner mem-
branous layer, the intima pia, and a more superficial epipial layer. The intima pia, 
adherent to the underlying nervous tissue, follows its contours closely. The epipial 
layer is formed by a mesh network of collagenous fiber bundles continuous with the 
arachnoid trabeculae, as what we call an intermediate leptomeningeal. The blood 
vessels of the spinal cord lie within this epipial layer. This intermediate leptomenin-
geal layer is closely applied to the innermost aspect of the arachnoid membrane; it 
reflects to form the dorsal septum and arborizes over the dorsal surface of the spinal 
cord, resulting in the formation of the epipial layer. The anterior spinal arteries and 
veins are arborized over by a dense epipial layer. The spinal cord is attached to the 
dura mater by a series of lateral, flattened bands of epipial tissue known as the den-
tate ligaments. The spinal dura mater extends around the spinal roots and nerves 
as they pass through the vertebral canal and the intervertebral foramina. These 
prolongations of spinal dura mater are called spinal nerve sheaths or root sheaths. 
The arachnoid within the sheaths does not extend as far as their dural coverings. 
Limited prolongation of the arachnoid demonstrates the nerve sleeves.
7. Surgical treatment
The posterior midline approach is most frequently used to remove tumors. Even 
ventrally located lesions can be safely resected via posterior approach. Dentate 
ligament resection allows for general mobilization of the spinal cord. Posterior 
roots can be sacrificed from C2 to C4 and throughout the thoracic region. Lower 
cervical and lumbosacral posterior roots should be preserved whenever possible. 
If it becomes necessary to sacrifice the sensory nerve root, it should be resected 
proximally to the ganglion to minimize postoperative neuralgia. Intracapsular 
decompression could be required for larger tumors. In a dumbbell-shaped tumor, 
the intradural portion should be resected first to minimize spinal cord manipula-
tion during the excision of the extradural component. The dura must be closed in a 
watertight fashion. In cases where a meningioma required resection of dura, a dural 
graft should be utilized for a watertight closure of the dura to prevent CSF leakage.
7.1 Intramedullary tumors
Surgery is the treatment of choice or the only effective treatment for intramed-
ullary spinal cord tumors. Most patients experience some loss of posterior column 
function following surgery due to the performance of the myelotomy through the 
posterior median septum. Due to the indolent feature of benign intramedullary 
tumors, it is important to optimize both the timing and the performance of surgery 
in these patients. The goals of surgical treatment are to preserve neurologic func-
tion and to maximize surgical removal. These goals are generally compatible, but 
the preservation of neurologic function should always come first. For patients with 
an incidental finding of asymptomatic intramedullary tumor, serial imaging and 
clinical follow-up are recommended. Once symptoms commence, then surgery is 
offered, before the onset of any substantial neurologic deficit, because surgery is 
usually not effective in reversing neurologic deficits.
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Illustration of a cross-section anatomy of the spinal cord showing deep anterior median fissure, shallow 
posterior median sulcus, and shallow grooves of anterolateral or posterolateral sulcus.
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the spinal cord projects directly downward, forming the filum terminale. The filum 
terminale, descending from the apex of the conus medullaris, is continued within 
extensions of the dural and arachnoid meninges and reaches the caudal border of 
the second sacral vertebra, stabilizing the entire spinal cord.
The spinal cord is covered by the meninges. The outermost membrane is the 
spinal dura mater which forms a tube. The spinal cord is directly covered by the 
thin, translucent membrane of the pia mater, which itself comprises an inner mem-
branous layer, the intima pia, and a more superficial epipial layer. The intima pia, 
adherent to the underlying nervous tissue, follows its contours closely. The epipial 
layer is formed by a mesh network of collagenous fiber bundles continuous with the 
arachnoid trabeculae, as what we call an intermediate leptomeningeal. The blood 
vessels of the spinal cord lie within this epipial layer. This intermediate leptomenin-
geal layer is closely applied to the innermost aspect of the arachnoid membrane; it 
reflects to form the dorsal septum and arborizes over the dorsal surface of the spinal 
cord, resulting in the formation of the epipial layer. The anterior spinal arteries and 
veins are arborized over by a dense epipial layer. The spinal cord is attached to the 
dura mater by a series of lateral, flattened bands of epipial tissue known as the den-
tate ligaments. The spinal dura mater extends around the spinal roots and nerves 
as they pass through the vertebral canal and the intervertebral foramina. These 
prolongations of spinal dura mater are called spinal nerve sheaths or root sheaths. 
The arachnoid within the sheaths does not extend as far as their dural coverings. 
Limited prolongation of the arachnoid demonstrates the nerve sleeves.
7. Surgical treatment
The posterior midline approach is most frequently used to remove tumors. Even 
ventrally located lesions can be safely resected via posterior approach. Dentate 
ligament resection allows for general mobilization of the spinal cord. Posterior 
roots can be sacrificed from C2 to C4 and throughout the thoracic region. Lower 
cervical and lumbosacral posterior roots should be preserved whenever possible. 
If it becomes necessary to sacrifice the sensory nerve root, it should be resected 
proximally to the ganglion to minimize postoperative neuralgia. Intracapsular 
decompression could be required for larger tumors. In a dumbbell-shaped tumor, 
the intradural portion should be resected first to minimize spinal cord manipula-
tion during the excision of the extradural component. The dura must be closed in a 
watertight fashion. In cases where a meningioma required resection of dura, a dural 
graft should be utilized for a watertight closure of the dura to prevent CSF leakage.
7.1 Intramedullary tumors
Surgery is the treatment of choice or the only effective treatment for intramed-
ullary spinal cord tumors. Most patients experience some loss of posterior column 
function following surgery due to the performance of the myelotomy through the 
posterior median septum. Due to the indolent feature of benign intramedullary 
tumors, it is important to optimize both the timing and the performance of surgery 
in these patients. The goals of surgical treatment are to preserve neurologic func-
tion and to maximize surgical removal. These goals are generally compatible, but 
the preservation of neurologic function should always come first. For patients with 
an incidental finding of asymptomatic intramedullary tumor, serial imaging and 
clinical follow-up are recommended. Once symptoms commence, then surgery is 
offered, before the onset of any substantial neurologic deficit, because surgery is 
usually not effective in reversing neurologic deficits.
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Cysts are frequently found at both ends of a tumor, which serve as landmarks in 
the dissection. The true tumor-cord interface needs to be carefully exposed, especially 
in possible cases of benign encapsulated tumors, with minimal damage to the spinal 
cord parenchyma. It is crucial to identify tumor-cord interface. When a clear tumor-
cord interface is difficult or the intraoperative appearance of the tumor suggests an 
anaplastic nature, further tumor removal is not warranted. Majority of intramedul-
lary ependymomas can be totally resected with preservation of neurologic function, 
as they usually have a clear plane of dissection. Resection of low-grade astrocytomas 
should be continued until the interface with the spinal cord is recognized. The 
interface is not always distinguishable. Surgical resection of more malignant astro-
cytomas is still controversial, as improvement of neurologic function is still unclear. 
Hemangioblastomas are well circumscribed and encapsulated neoplasms, so gross 
total resection can be achieved in nearly all cases. However, they are highly vascular, 
and vascular supply should be totally interrupted before the removal of the tumor. In 
general, assessment of the tumor-spinal cord interface under the operating micro-
scope is the most important factor in determining the specific surgical objective for 
each patient with a benign intramedullary lesion, irrespective of tumor histology.
7.2 Extramedullary tumors
The goal of management for patients with extramedullary spinal cord tumors 
is either long-term tumor control or cure with preservation of neurologic function. 
Surgery is clearly indicated in patients with symptomatic tumors particularly those 
with large tumors producing significant compression of the spinal cord or cauda 
equina. For patients with smaller tumors or those with minimal subjective symptoms, 
it may be considered to follow them both over time. For small and asymptomatic 
tumors, regular radiographic surveillance can also be recommended. However, 
midline filum/cauda equina tumors are usually ependymomas in nature, which can 
disseminate through CSF; therefore, an early total resection of these lesions is recom-
mended. The vast majority of intradural-extramedullary tumors can be safely accessed 
and removed through a standard posterior laminectomy. Even most ventrally located 
tumors can be accessed posteriorly because lateral spinal cord displacement or rotation 
enables a safe corridor to debulk and remove most ventrally located tumors. However, 
pure ventral lesions may require a more lateral or, rarely, an anterior approach. 
Intraoperative ultrasound can be used to identify the location of the tumor levels. 
Dumbbell tumors with epidural extension into the neural foramen usually require a 
unilateral facetectomy to allow access to foramina, followed by instrumented fusion 
extending one level above and below the facetectomy. Whenever possible, it is prefer-
able to remove the tumor through a single operative exposure to reduce morbidity and 
preserve surgical options. Debulking is recommended when the tumor is large. As the 
tumor is mobilized, the nerve stimulator is used to identify motor roots. Once the root 
or rootlet of origin has been identified, it is sectioned both proximally and distally, and 
the tumor is removed. If the tumor extends into the extradural space, motor stimula-
tion is essential to determine whether there is motor root involvement. If there is no 
motor root stimulation, the entire root can be sacrificed. However, a functional motor 
root involved by tumor should be spared to avoid a significant postoperative neuro-
logic deficit, even though this produces a subtotal resection.
8. Technical advances and adjunctive options
Ultrasonic surgical aspiration: this device consists of a hollow tube that vibrates 
at high frequencies and physically emulsifies the tumor while irrigating and 
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aspirating the field. It improves the debulking of spinal tumors. When placing the 
aspirator tip in contact with the tumor, the surgeon can achieve a relatively atrau-
matic resection of the tumor, without manipulation of the adjacent spinal cord. 
Additionally, the ultrasonic aspirator allows preservation of blood flow in adjacent 
tissue.
8.1 Intraoperative ultrasonography
With an ultrasonic transmitter placed over the spinal cord, intraoperative ultra-
sonography can help identify the location of the tumor, existence of intramedullary 
cysts, and the relationship between the spinal cord and the surrounding structures. 
Prior to dural opening, bony exposure can be adjusted, which could reduce the pos-
sibility of further bone removal after dural opening and minimize the risk of direct 
injury of the exposed neural structures. The integration of intraoperative ultraso-
nography and microscope allows for a better visualization of the surgical field and 
to facilitate tumor resection. It can also assist with identifying any residual tumor 
tissue after resection. A color flow Doppler ultrasound can be utilized for a vascular 
tumor like hemangioblastoma or in a case where major vasculature structure has 
been involved. By allowing the evaluation of the anatomy underneath surgical field 
surface, intraoperative ultrasonography can help in refining the surgical strategy.
8.2 Intraoperative neurophysiological monitoring
Intraoperative neurophysiological monitoring has gained popularity with 
surgeons when it comes to a surgical resection of intramedullary tumor. 
Somatosensory evoked potential (SSEP) and transcranial motor evoked potential 
(MEP) are the most commonly used techniques which continuously monitor sen-
sory and motor potentials individually during surgery for intramedullary tumors. 
With transcranial MEP, motor pathways are stimulated centrally, and responses 
can be recorded directly from needle electrodes placed in the extremities’ muscles. 
Myogenic MEP waveforms recorded from muscles can be categorized into three 
patterns: polyphasic, biphasic, and absent. An electrophysiologist will view and 
record waveforms and their changes and report any possible adverse reactions to the 
descending motor pathways related to the surgery. Intraoperative neurophysiologi-
cal monitoring is not absolutely reliable, as a change in potential may not present 
until up to 1 minute after the occurrence of the injury [8]. Due to the proximity of 
the corticospinal and spinothalamic tracts, as well as the dorsal columns, intraop-
erative injury to the motor pathways can be reflected in changes in sensory evoked 
potentials. MEP monitoring can be used to avoid excessive spinal cord manipula-
tion and improve the surgical technique during resection of the tumor. Amplitude 
changes in MEP have been examined to be strongly correlated with postoperative 
neurologic function [9, 10].
9. Outcome of treatment
9.1 Intramedullary tumors
With aggressive surgical resection as the treatment of choice, postoperative 
neurologic outcome is closely related to the patient’s preoperative neurologic status. 
In general, better postoperative neurologic outcome occurs with lesser preopera-
tive neurologic deficits [11]. It has been argued that postoperative deterioration of 
neurologic function, regardless of being transient or permanent, is attributed to 
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tion and improve the surgical technique during resection of the tumor. Amplitude 
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In general, better postoperative neurologic outcome occurs with lesser preopera-
tive neurologic deficits [11]. It has been argued that postoperative deterioration of 
neurologic function, regardless of being transient or permanent, is attributed to 
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direct surgical insult to either the spinal parenchyma or the spinal cord circulation. 
When a posterior median sulcus approach is used, patients may present posterior 
column dysfunction early after surgery, including abnormalities of discriminative 
touch sensation, proprioception, or gait [12]. These symptoms may or may not be 
permanent. Neuropathic pain syndrome can present after surgery when syringomy-
elia is associated with the lesion.
When low-grade astrocytoma is associated with a cyst, a clear interface can 
be identified between the tumor and the spinal cord; a gross total resection of 
the lesion is optimal. This will halt the clinical and radiological progression of the 
tumor for many months. Due to the infiltrative nature of high-grade astrocytoma, 
radical resection of the lesion is not feasible without damaging the normal spinal 
cord tissue. Progression of low-grade astrocytoma into high-grade tumor can occur, 
which then further affects the outcome. For patients with ependymomas, long-term 
survival is expected, especially as total resection of the tumor is widely adopted. 
In comparison to astrocytoma, the outcomes of ependymomas do not appear to 
be related to histologic grades of the tumor. Although rare, CSF dissemination of 
ependymoma does occur.
9.2 Extramedullary tumors
Regardless of tumor histology, location, and extent of lamina resection, the sur-
gical outcomes of extramedullary tumors are optimal in general [13, 14]. However, 
an early surgical intervention is recommended for symptomatic lesions, as it is 
associated with a greater postoperative improvement [13]. Neurologic complica-
tions are uncommon, and even if they do occur, improvement could be expected 
in majority of the cases. Improvement of initial neurologic deficits can be expected 
for months and up to a year after tumor resection. Provided that a gross resection 
has been obtained, recurrence rarely occurs [15]. In the case where recurrence does 
occur, reoperation is usually not required instantly and largely contingent on the 




The incidence of CSF leakage remains high after spinal cord tumor surgeries 
involving opening of the dura mater. It is more commonly seen in the upper thoracic 
region. Radiation therapy prior to the surgery is a risk factor for patient to develop 
a CSF leak. Improper treatment of CSF leakage can potentially give rise to other 
complications including CSF fistula, meningitis, abscess, and even neurological 
deficits [16].
Management of CSF leakage entails two aspects based on CSF dynamics [17]: 
to prevent CSF leak with direct watertight closure of the dura mater and to retard 
CSF leak by reducing the subarachnoid CSF pressure and/or increasing the epi-
dural space pressure. Prevention is of great importance in managing CSF leakage 
complication. A watertight closure of the dura mater is crucial, and a direct suture 
with adjuvant dural closure material has gained popularity among spinal surgeons 
owing to its high successful rate in watertight closure [18, 19]. At times the involved 
dura has been inevitably excised, and this renders a primary closure impossible. 
In this case, an augmented closure with the aid of an adipose tissue, muscle tissue, 
or fascial graft would be indicated. The graft would be layered over the defect of 
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dura mater, and prolonged bed rest with a wound drainage would be warranted 
to avoid a CSF leakage [20–22]. In the event of CSF leakage development, tech-
niques reducing the subarachnoid fluid pressure would be exploited. This includes 
inhibiting the formation of CSF with medications such as acetazolamide, adjusting 
patient’s position, and CSF shunting with a lumbar drain placement [16, 23]. These 
approaches have been proven effective, although complications do occur pertinent 
to the treatment [24, 25].
CSF leakage is a vexing problem and usually requires prolonged postoperative 
treatment. Should CSF leakage persist, surgical exploration of proper dura closure 
may deem necessary and should not be delayed.
10.2 Postoperative instability
Due to the generally optimal neurological outcome of extramedullary spinal 
tumors, a rising attention has been turned to the long-term outcome after tumor 
resection involving a spine procedure. Postoperative iatrogenic instability has been 
recognized throughout different spine segments, including cervical kyphosis after 
laminectomies, thoracic instability after laminoforaminotomy-facet resections, and 
spondylolisthesis after lumbar laminectomies [26, 27]. This has been attributed to 
the alteration in spine biomechanics as a result of extensive laminectomies with or 
without facetectomies [28]. Postoperative instability is associated with preoperative 
instability, extent of facetectomy, level of spine segments involved, and disruption 
of ligamentous structures. Stabilization is warranted in patient demonstrating pre-
existing spine instability. An increasing number of levels involved entail more dis-
ruptions of structural components during the procedure, which results in a higher 
risk of postoperative instability [29]. A biomechanical model study has shown that 
removing the medial one third to one half of the facet joint as well as the posterior 
ligaments destabilizes the spine by significantly increasing spinal flexion by nearly 
12° [30]. Instrumented fusion that extends one level above and below the facetec-
tomy is usually performed. If instability happens, it should be identified early, and 
a stabilization procedure should be performed to arrest the progression. In patients 
who are treated with cervical region tumors involving extensive laminectomies, 
stabilization is routinely applied. Post-laminectomy kyphosis is exceedingly dif-
ficult to treat; thus, surgical stabilization is imperative to preempt this [31].
Minimal invasive procedures have prevailed among spinal surgeons; however, 
their indications are largely contingent on each individual case, and their efficacies 
in preventing instability have yet to be determined.
11. Summary
Substantial advancement of neuroradiology and its wide adoption in clinical set-
tings have improved the recognition of spinal cord tumors. Many lesions have now 
been identified on MRI before they become symptomatic clinically. Early recogni-
tion has offered physicians the advantage of managing and treating these tumors 
in the early course of the disease. General refinement of surgical techniques and 
adjunctive technologies has undeniably improved the outcome of the disease while 
minimizing neurologic deficits.
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direct surgical insult to either the spinal parenchyma or the spinal cord circulation. 
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elia is associated with the lesion.
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tumor for many months. Due to the infiltrative nature of high-grade astrocytoma, 
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cord tissue. Progression of low-grade astrocytoma into high-grade tumor can occur, 
which then further affects the outcome. For patients with ependymomas, long-term 
survival is expected, especially as total resection of the tumor is widely adopted. 
In comparison to astrocytoma, the outcomes of ependymomas do not appear to 
be related to histologic grades of the tumor. Although rare, CSF dissemination of 
ependymoma does occur.
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an early surgical intervention is recommended for symptomatic lesions, as it is 
associated with a greater postoperative improvement [13]. Neurologic complica-
tions are uncommon, and even if they do occur, improvement could be expected 
in majority of the cases. Improvement of initial neurologic deficits can be expected 
for months and up to a year after tumor resection. Provided that a gross resection 
has been obtained, recurrence rarely occurs [15]. In the case where recurrence does 
occur, reoperation is usually not required instantly and largely contingent on the 
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niques reducing the subarachnoid fluid pressure would be exploited. This includes 
inhibiting the formation of CSF with medications such as acetazolamide, adjusting 
patient’s position, and CSF shunting with a lumbar drain placement [16, 23]. These 
approaches have been proven effective, although complications do occur pertinent 
to the treatment [24, 25].
CSF leakage is a vexing problem and usually requires prolonged postoperative 
treatment. Should CSF leakage persist, surgical exploration of proper dura closure 
may deem necessary and should not be delayed.
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Due to the generally optimal neurological outcome of extramedullary spinal 
tumors, a rising attention has been turned to the long-term outcome after tumor 
resection involving a spine procedure. Postoperative iatrogenic instability has been 
recognized throughout different spine segments, including cervical kyphosis after 
laminectomies, thoracic instability after laminoforaminotomy-facet resections, and 
spondylolisthesis after lumbar laminectomies [26, 27]. This has been attributed to 
the alteration in spine biomechanics as a result of extensive laminectomies with or 
without facetectomies [28]. Postoperative instability is associated with preoperative 
instability, extent of facetectomy, level of spine segments involved, and disruption 
of ligamentous structures. Stabilization is warranted in patient demonstrating pre-
existing spine instability. An increasing number of levels involved entail more dis-
ruptions of structural components during the procedure, which results in a higher 
risk of postoperative instability [29]. A biomechanical model study has shown that 
removing the medial one third to one half of the facet joint as well as the posterior 
ligaments destabilizes the spine by significantly increasing spinal flexion by nearly 
12° [30]. Instrumented fusion that extends one level above and below the facetec-
tomy is usually performed. If instability happens, it should be identified early, and 
a stabilization procedure should be performed to arrest the progression. In patients 
who are treated with cervical region tumors involving extensive laminectomies, 
stabilization is routinely applied. Post-laminectomy kyphosis is exceedingly dif-
ficult to treat; thus, surgical stabilization is imperative to preempt this [31].
Minimal invasive procedures have prevailed among spinal surgeons; however, 
their indications are largely contingent on each individual case, and their efficacies 
in preventing instability have yet to be determined.
11. Summary
Substantial advancement of neuroradiology and its wide adoption in clinical set-
tings have improved the recognition of spinal cord tumors. Many lesions have now 
been identified on MRI before they become symptomatic clinically. Early recogni-
tion has offered physicians the advantage of managing and treating these tumors 
in the early course of the disease. General refinement of surgical techniques and 
adjunctive technologies has undeniably improved the outcome of the disease while 
minimizing neurologic deficits.
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